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SUMMARY 
This study describes: 
 the evaluation of the current, and potential assay methods for the quantification of 
cholesterol, cholesteryl esters and free fatty acids in milk and the application thereof; 
 an account of the difficulties associated with the usage of FoodPro® Cleanline, an enzyme 
preparation used as processing aid, during ultra-high temperature processing of milk; 
 the development of activity assays which can be used for the kinetic characterization of 
glycerophospholipid cholesterol acyltransferase, the active enzyme in FoodPro® Cleanline; 
 the development of an accurate and facile activity assay, and the validation thereof, which 






Hierdie studie beskryf: 
 die evaluering van die huidige, en potensiële, metodes vir die kwantifisering van 
cholesterol, cholesteriel esters en vryvetsure in melk, sowel as die toepassing van hieridie 
metodes; 
 „n verduideliking van die moeilikhede wat ondervind word gedurende die gebruik van 
FoodPro® Cleanline, „n ensiempreparaat vir gebruik as „n verwerkingshulpmiddel, tydens 
ultrahoë-temperatuurprosessering van melk; 
 die ontwikkeling van aktiwiteitsbepalings metodes vir gebruik in kinetiese karakterisering 
van gliserofosfolipied cholesterol asieltransferase, die aktiewe ensiem in FoodPro® 
Cleanline; 
 die ontwikkeling van „n akkurate, eenvoudige aktiwiteitsbepalings metode, en bevestiging 
van hierdie metode, wat gebruik kan word vir kwalitieitskontrole alvorens die dosering van 
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CHAPTER 1  
INTRODUCTION 
At present, milk is considered to be one of the safest foods commercially available. It is 
therefore difficult to comprehend that barely 200 years ago milk was considered “as deadly as 
Socrates‟ hemlock”1. At that time, milk was commonly consumed at ambient temperature 
without prior thermal treatment. Because milk is a rich source of nutrients, designed to sustain 
the mammalian neonate, it provides the optimal conditions for the proliferation of, often fatal, 
microorganisms at ambient temperatures. As a result the usage of milk often resulted in high 
mortality rates, especially in infants. During the early 19th century Louis Pasteur discovered that 
mild heat treatment of foods can increase shelf life by killing the microorganisms responsible for 
spoilage2. This treatment was subsequently applied to milk intended for use by infants. Although 
thermal treatment of milk was rigorously opposed, the introduction of thermally processed milk 
coincided with a sharp decrease in infant mortality. 
Since the advent of thermal treatment of milk, fouling has been a major problem leading to 
increased costs due to plant down-time and the need for cleaning chemicals. Thermal 
processing results in the denaturation of heat labile milk proteins, mainly β-lactoglobulins, and a 
decrease in the solubility of minerals such as calcium phosphate3–5. The denatured proteins 
subsequently form aggregates which adhere to the heat transfer surfaces of indirect thermal 
processing plants in a process known as fouling3,4. At temperatures in excess of 105°C this 
layer of proteinaceous material acts as a scaffold for the subsequent deposition of minerals 
resulting in mineral fouling3. The foulant layer reduces the heat transfer capacity of the heat 
exchangers by insulating the heat source from the product. To maintain a constant product 
temperature, the temperature of the heating medium needs to be increased. As a result, the 
energy cost of processing increases with the degree of fouling. Fouling may also result in 
product deterioration by ineffective heating and contamination with dislodged deposits5. In order 
to avoid excessive fouling, the heat exchangers should be cleaned on a regular basis (at least 
once a day). A typical clean in position (CIP) cycle can take as much as 2 hours of processing 
time and requires high volumes of harmful cleaning chemicals. These factors greatly increase 
the overall processing cost during the production of UHT milk. As a result, fouling, and the 
prevention thereof, has been exhaustively investigated4–6.  
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Ultra high temperature (UHT) treatment of milk involves the treatment of milk at 142°C for a 
minimum of 2 seconds. This form of thermal treatment is sufficient to destroy all vegetative 
microbial cells and their spores. As a result, UHT treated milk has an increased shelf life when 
stored at ambient temperatures. In combination with a high nutritional value, UHT milk has great 
potential as nutritional aid in areas without sufficient cold chain storage infrastructure and areas 
struck by natural disasters. However, mineral fouling, during UHT processing, greatly increases 
the overall cost of production, reducing its availability in rural areas. 
Since it is known that protein fouling precedes mineral fouling, and is a prerequisite thereof, it is 
conceivable that elimination of protein fouling could also eliminate mineral fouling. It has been 
shown that protein fouling can be reduced by stabilization of proteins denatured during thermal 
processing. This was achieved by the addition of emulsifiers, such as lecithin, to raw milk prior 
to thermal processing7–9. However, the use of lecithin for this purpose, in drinking milk, not only 
introduces an allergen, but is also prohibited by law. More recent studies have indicated that the 
addition of lipases can increase cheese yield during production. It was subsequently shown that 
this increase is due to the production of amphoteric surface active lysophospholipids by 
phospholipid hydrolysis. It has furthermore been shown that emulsions stabilized by 
lysophospholipids have increased heat stability and a lower sensitivity to flocculation by Ca2+ 
and Mg2+10–12. This increase in heat stability has been attributed to the formation of 
lysophospholipid-protein complexes at droplet interfaces12–15. As such, the addition of lipases to 
raw milk, prior to thermal processing, may reduce fouling by increasing the heat stability of milk 
proteins. However, although the reaction of lipases with phospholipids yields lysophospholipids, 
this interaction also results in the formation of free fatty acids. Free fatty acids are known to 
increase the acid degree of milk resulting in an increase in rancidity. Furthermore, milk contains 
various native lipases which need to be inactivated as quickly as possible to prevent spoilage of 
the raw milk. Addition of foreign lipases is therefore not recommended. 
Members of the genus Aeromonadaceae have been shown to produce a lipase-like enzyme 
glycerophospholipid cholesterol acyltransferase (GCAT, EC 2.3.1.43) which is able to transfer a 
fatty acyl chain from the two-position of phospholipids to a suitable acceptor such as 
cholesterol. In this reaction lysophospholipids and cholesteryl esters are produced. Free fatty 
acids are therefore sequestered in cholesteryl esters and would, as a result, not increase the 
acid degree value of raw milk. This enzyme has since been isolated, cloned, expressed and 
purified by DuPont® for the potential application in the dairy industry, to reduce fouling during 
UHT treatment, under the commercial name FoodPro® Cleanline (FPCL). Since enzyme 
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catalysis is highly specific, the use of enzymes could enable production of products with 
predetermined qualities. This information could furthermore be applied to development of a 
dosage model which could be used to predict the final product qualities. However, to the best of 
our knowledge, the kinetic characteristics of GCAT catalysis, which would allow for the accurate 
dosing of this enzyme, have not yet been published. 
During pilot- and full scale FoodPro® Cleanline (FPCL) application trials, at different venues, 
conflicting results were obtained. The results were furthermore not consistent when the trials 
were repeated. The reason for these inconsistencies could not be explained. For successful 
industrial marketing and application of FPCL, these difficulties had to be overcome and 
eliminated. For this reason, and for quality control purposes, accurate and reproducible methods 
for the quantification of FPCL reaction products must be in place. Availability of kinetic data for 
the interaction between GCAT and its substrates would enable dosage optimization to produce 
a product with predetermined characteristics.  
For the results presented in this thesis FPCL application trials were repeated in an attempt to 
determine the potential problems which may be associated with the commercial application of 
FPCL. Methods for the quantification of GCAT reaction products, cholesteryl esters and FFA in 
milk was evaluated. These methods were subsequently used during the kinetic characterization 
of the GCAT enzyme. The thesis concludes with a description of the development of a novel 
activity assay, and kinetic verification thereof, for the accurate determination of FPCL activity. 
This work is presented in Chapter 5. Finally, the newly developed assay will be used for FPCL 
applicability studies. The current work therefore had the following aims: 
1. To perform pilot- and factory scale FPCL application trials in order to define the 
difficulties associated with the usage of FPCL. 
2. Evaluation of the current, and potential, assay methods for the quantification of GCAT 
reaction products in milk and the application thereof. 
3. The adaptation of existing activity assays to enable kinetic characterization of GCAT. 
4. The development of an accurate GCAT activity assay for use in FPCL activity validation. 
5. The verification of the newly developed assay by comparison to assays performed using 
the natural substrates for GCAT. 
The studies conducted will be presented as follows: 
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Chapter 2 presents an introduction and overview of fouling in the dairy industry followed by a 
review of the GCAT enzyme. The current understanding of fouling and the existing methods for 
its prevention are addressed in detail. The history, purification, molecular characteristics and 
mechanism of action of the GCAT enzyme will subsequently be discussed with particular 
attention to the mechanism of action using different substrates, both natural and synthetic.  
Chapter 3 reviews the current, and potential, methods for quantification of FPCL activity. The 
current difficulties associated with FPCL activity monitoring will be discussed with specific 
reference to the nature of the natural substrates, phospholipids and cholesterol. Potential 
substrates for use in kinetic characterization will be described in detail. The possibility for 
application of synthetic substrates for the development of a facile continuous activity assay will 
be reviewed, concluding with the outstanding work in enzyme characterization. 
In Chapter 4 the current method for quantification of FPCL reaction products and free fatty acids 
are described and evaluated. The results from pilot- and factory scale FPCL trials performed 
throughout 2012 will be presented and discussed with particular mention to the previously found 
inconsistencies. This chapter will conclude in the identification of the possible reasons, and 
remedies, for the conflicting results obtained in previous studies conducted with FPCL 
elsewhere. 
Chapter 5 describes the evaluation of different methods for the quantification of FPCL reaction 
products in milk. These methods will subsequently be used in the development of enzyme 
activity assay which would enable kinetic characterization of GCAT and the accurate monitoring 
of FPCL activity. The current work will attempt to validate the newly developed assay method by 
comparison of kinetic parameters obtained from kinetic studies. This chapter will conclude in the 
use of synthetic substrates for the evaluation of FPCL applicability in different milk processing 
methods. 
In conclusion, Chapter 6 presents an overview of the results obtained during the course of this 
study. The current difficulties with FPCL activity monitoring and evidence for the current theory 
for the catalytic mechanism of GCAT will be discussed. This chapter will conclude in the 
discussion of potential substrates for use in GCAT activity studies. 
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CHAPTER 2  
THERMAL PROCESSING IN THE DAIRY INDUSTRY 
2.1 INTRODUCTION 
Milk is a complex biological mixture, consisting of proteins, carbohydrates, minerals, lipids, 
vitamins and trace elements, essential to normal physical and mental development. Large scale 
production of milk is a challenging exercise. The nutrient rich nature of milk provides optimal 
conditions for microbial growth leading to the rapid spoilage of the raw product. As a result, 
various processing techniques have been applied to enhance the safety and quality of the final 
product, including extending the shelf life. Ultra-high temperature (UHT) processing can extend 
product shelf life for up to 12 months16. As thermal processing is an energy intensive process, 
wherein products are heated at least once, the efficiency of the heating process is of paramount 
importance in order to ensure economic viability. Temperature induced fouling, however, 
reduces processing efficiency significantly, leading to product deterioration and an increased 
overall processing cost 5,17. 
Fouling of heat exchangers by dairy products has been a major problem since the advent of 
thermal processing of dairy products in the 1930s4. The fouling phenomenon, in the dairy 
industry, can be described as the temperature induced formation of deposits on the heat 
exchanging surfaces. Deposit formation reduces the heat transfer efficiency of the heat 
exchanger by insulating the product from the heat source. Consequently, overall processing 
cost is significantly increased by the need for additional energy input due to reduction of heat 
transfer efficiency, manpower, loss in productivity, cleaning chemicals and the environmental 
impact3,18. Fouling may furthermore result in product deterioration, by contamination with 
dislodged deposits, and inefficient heating during thermal processing. For these reasons, daily 
intermediate plant shutdown and cleaning is essential to maintain optimal product quality and 
processing efficiency3.  
Although a significant volume of research has been done into the reduction of temperature-
induced fouling, the underlying factors affecting fouling are still poorly understood. Recent 
advances in lipase enzyme technology have shown promise by harnessing the natural 
emulsifying potential of milk lipids. Lipases hydrolyze phospholipids to yield lysophospholipids 
(LPL) which can stabilize denatured milk proteins. The use of lipases in various industrial 
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applications is well established. Enzyme catalysis is highly specific, active under mild reaction 
conditions and reduces non-specific by-products19,20. Enzymes are furthermore active at low 
concentrations and are often fully inactivated by UHT processing temperatures. For these 
reasons enzymes are well suited for use in the food, and especially the milk industry. In the 
ensuing section the current understanding of the mechanism of dairy fouling and the practical 
procedures for its limitation will be discussed in more detail.  
2.2 FOULING   
2.2.1 Types of fouling 
The composition of the deposit layer on heat exchangers varies in relation to processing 
temperature. Two types of fouling have been described. Type A fouling describes the deposition 
of proteinaceous material at temperatures between 80 and 105°C4,21. The deposit layer formed 
in type A fouling, generally known as protein fouling, occurs as a relatively soft bulky layer 
consisting of 50-60% protein, 30-50% minerals and 4-8% fat3,4,18. Although milk proteins 
constitutes only a small amount of the total milk solids (< 5%), they account for more than 50% 
of the fouling deposits in type A fouling.  
The two major whey proteins are β-lactoglobulin and α-lactalbumin, however, β-lactoglobulin is 
the major protein involved in fouling due to its heat sensitive nature3,5,18. Upon heating of milk, 
the β-lactoglobulins denature and expose reactive sulfhydryl groups3,5. This denatured form of 
β-lactoglobulin is known as the activated form of the protein since it is able to associate with 
itself or other milk proteins via disulfide bond formation to form protein aggregates3,21. The exact 
mechanism of fouling is not yet fully understood, however, a relationship between denaturation 
of β-lactoglobulin and UHT fouling has been previously established22. Figure 2.1 depicts the 
proposed mechanism of fouling as described by Britz and Robertson21. As shown in Figure 2.1, 
β-lactoglobulins are activated by heat, resulting in increased aggregation and, ultimately, 
deposition and fouling of the heat exchangers.  
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Figure 2.1 Mechanism of fouling wherein β-lactoglobulin is activated by thermal processing, resulting in the formation 
,and adhesion, aggregates on the heat exchange surfaces
21
. 
Type B fouling, otherwise known as mineral fouling, occurs when processing is performed at 
temperatures in excess of 105°C. The deposit layer in mineral fouling is hard, granular in 
structure and consists of 70-80% minerals (mainly calcium phosphate), 15-20% protein and 4-
8% fat4. The mineral content of milk is only about 1% in weight, however, minerals such as 
calcium phosphate constitutes up to 70% of the deposits of Type B fouling23. The solubility of 
calcium phosphate decreases with increasing temperature. Consequently, mineral fouling 
occurs due to a local supersaturation of calcium phosphates next to the heat exchanging 
surfaces upon precipitation of these minerals17,23. The mechanism of mineral fouling is better 
understood than that of protein fouling, however, a complete discussion of this process is 
beyond the scope of this thesis. 
2.2.2 Mineral deposition is preceded by protein deposition 
Fouling has generally been regarded as at least a two-step process, starting with an induction 
period followed by adsorption of proteins to the heat exchanging surfaces4,5,24. It was concluded 
by Foster25, that mineral deposition occurs only after the exchanger surface has been covered 
by a thin layer of proteinaceous material. Mineral depositions subsequently diffuse through the 
deposit layer to the deposit-metal interface26,27. Protein fouling therefore acts as a scaffold for 
mineral fouling to build on. This theory is supported by the observation that an increase in the 
calcium content of milk, prior to thermal processing, increases the degree of fouling by 
decreasing the denaturation temperature of β-lactoglobulin5,26,28. Addition of potassium iodate 
on the other hand reduces fouling by oxidizing the sulfhydryl groups exposed by heat induced 
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protein denaturation26,27. Oxidation of these groups prevents protein aggregation resulting in a 
reduced degree of fouling. These results indicate that protein denaturation and aggregation is 
the key step in fouling. Supportive of this, various authors have shown that fouling is increased 
with an increase in milk protein concentration26,29. A reduction in protein fouling would therefore 
lead to an overall reduction in fouling. 
2.2.3 Preventative measures for fouling 
Although UHT fouling may be practically unavoidable, it may be minimized by various factors. 
The most important factors affecting milk fouling are the operating conditions in the heat 
exchanger, the composition of milk and the type and characteristics of heat exchangers. Milk 
composition varies with the age, breed, feeding conditions, season, udder health status and the 
stage of lactation of the cow30,31. Seasonal changes in the total milk protein concentration have 
been shown to affect fouling directly. However, these factors cannot be readily controlled in an 
attempt to reduce fouling. Considerable attention has therefore been concentrated on the 
operating conditions as well as the characteristics of the heat exchanger. Such attempts have, 
however, been met with limited success.  
2.2.3.1 Operational measures for minimization of fouling 
During thermal processing various operational parameters, such as the air content, 
velocity/turbulence, and temperature, contribute to fouling of the heat exchanger5. The solubility 
of air in milk decreases with an increase in temperature. Dissolved air is consequently released 
during thermal processing resulting in the formation of air bubbles. Deposit formation is 
mitigated when the air bubbles form next to heating surfaces. These bubbles subsequently act 
as nuclei for deposit formation due to local overheating of the heating surfaces4–6. Bubble 
formation may be suppressed by including a degassing step prior to thermal processing, or by 
increasing the operational back pressure. An increase in back pressure will act to keep the 
dissolved air in solution. An increase in flow velocity and turbulence has also been shown to 
reduce fouling. Higher flow velocities act to increase fluid shear stresses promoting deposit re-
entrainment5. Inclusion of a preheating step may also reduce fouling by promoting the 
denaturation of β-lactoglobulin, and its association with casein (κ-casein) micelles3,7. The casein 
micelles not only associate with denatured protein, but also with calcium phosphate reducing 
the availability of the main constituent of type B fouling3.  
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The surface characteristics of indirect heat exchangers also affect the rate of deposit formation. 
Adsorption of proteins to the heat exchanging surfaces is the rate limiting step in fouling. 
Surface modifications such as electro-polishing and surface coatings can therefore reduce 
surface roughness and wettability. Such modifications may reduce the adhesion strength of 
deposits to the heating surfaces. However, surface treatment is only beneficial until the heating 
surface has been covered with a layer of deposits. Whey protein adsorption leads to a 
demetallizing effect of the heat exchanger surface4. The benefit of surface treatment may 
therefore not lie with the reduction of fouling during thermal processing, but with simplifying the 
removal of deposits after processing. 
2.2.3.2 Alternatives to conventional steam heating 
Although commercial direct heating plants generally use superheated steam as the heating 
medium, other heating methods such as microwave-, ohmic- and induction- heating are 
available that do not require any heating medium. These methods have been gaining popularity 
due to a reduction in final product dilution as well as a reduction in fouling3,5. However, even 
with these methods, fouling cannot be eliminated completely.  
Microwave heating methods have been employed in various industrial applications due mainly 
to its heating efficiency, energy saving and compactness. Unfortunately microwave systems 
have a limited lifespan. This method is therefore not economically viable for all applications5. In 
ohmic heating an electric current is passed through the product causing an uniform increase in 
temperature due to resistance against the current by the fluid32. This method increases 
efficiency by eliminating inefficient mechanisms such as heat transmission from a heating 
medium to the product. Ohmic heating have various advantages among which a lack of moving 
parts, uniform heating and instantaneous start/stop cycles are the most important. Nevertheless, 
the electrode surfaces are susceptible to deposition and erosion5,32. The use of high voltages 
also necessitates additional safety requirements. In induction heating product temperature is 
increased by oscillation of magnetic fields inside electric coils. This oscillation causes an electric 
current which heats the product5. Induction heating systems are energy efficient since no heat is 
wasted during heat transmission. The main disadvantage of induction heating systems is the 
dependence on magnetic boilers. Stainless steel, predominantly used in the dairy industry for 
hygienic purposes, is not magnetic and can therefore not be used for induction heating.  
Fouling in the abovementioned heating systems are furthermore more problematic than with 
conventional heating. A deposition layer causes a difference in product heating properties, 
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resulting in non-uniform heating. Localized heating in the deposit layer promotes further fouling 
by creating a temperature difference on the fluid/deposit interface5. The major disadvantage of 
the above mentioned heating procedures is that existing UHT plants cannot be readily adapted 
to employ these heating methods. Altering heating systems would require re-fitting of the entire 
plant, resulting in extended periods of downtime. The use of these heating systems is therefore 
limited in established dairy industries. 
2.2.4 The use of additives 
A significant amount of research has been focused on the minimization of fouling by the 
optimization of operational parameters, such as inclusion of a preheating step, and the type and 
characteristics of the heat exchangers. Unfortunately these approaches have been met with 
limited success, mainly due to the complex nature of milk. As discussed previously, the 
composition of milk cannot be readily controlled. However, milk composition can be modified by 
the addition of various additives such as emulsifiers and enzymes. The use of such additives, 
however, necessitates adherence to national, and international, regulations with regards to 
labeling. 
2.2.4.1 Emulsifiers 
Emulsifiers are widely used in the dairy industry in order to control the stability and molecular 
structure of various products. Such additives are surface active amphiphiles, which act as 
biosurfactants. In colloidal solutions, such as milk, surfactants are able to associate with both 
the aqueous and oil phase at the interface where it acts to lower the surface or interfacial 
tension7. It has been shown that the natural emulsifier lecithin can be used to increase the heat 
stability of homogenized and concentrated milks7. The exact mechanism whereby lecithin 
increases heat stability is not yet fully understood. However, it has been proposed that, as with 
inclusion of a preheating step prior to UHT processing, lecithin promotes complex formation 
between κ-casein and β-lactoglobulin7,33,34. Various authors also believe that lecithin-protein 
interactions may play a role in the heat stability of some dairy products7–9.  
The use of lecithin may therefore reduce fouling by promoting protein stability during thermal 
processing of milk. However, the Foodstuffs, Cosmetics and Disinfectants Act (No. 54 of 1972), 
prohibits the use of any additive, including lecithin, in milk without proper labeling35. Milk 
products containing additives should be labeled accordingly, and is considered a blended-milk 
product as opposed to drinking milk. Furthermore, food grade lecithin is mainly a soy product 
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which is considered an allergen. The use of lecithin to reduce fouling is therefore not allowed 
during the production of products classified as drinking milk. 
2.2.4.2 Enzymes 
Since the ancient times, enzymes have played an indispensible role in food production. In the 
dairy industry, enzymes are used for many applications such as the production of cheese 
(rennet), to increase customer satisfaction (lactase enzymes) and to improve overall product 
texture and flavor (lipases). Since enzymes catalyze specific reactions, they can be applied to 
yield specified products. The most common enzymes currently used in the dairy industry include 
rennet, proteases, lactases, catalases and lipases36. 
Recently, a class of phospholipases, phospholipase A1 (EC 3.1.1.32), have been applied in the 
dairy industry to increase cheese yield37. Phospholipase A1 catalyzes the 1-position specific 
hydrolysis of phospholipids yielding LPL and free fatty acids (FFAs) as products11,38–40. LPL are 
a class of amphoteric surface-active surfactants which are less hydrophobic than their 
phospholipid counterparts11. An increase in water-solubility results in increased dynamic surface 
activity due to a higher concentration in the aqueous phase10,11,15. Emulsions stabilized by LPLs 
have been shown to have improved heat stability and a lower sensitivity to flocculation by Ca2+ 
and Mg2+ 10–12 . Furthermore, emulsions stabilized by LPL are less susceptible to fluctuations in 
pH41,42. Such emulsions therefore have improved stability over a wider pH and temperature 
range. 
The increase in heat stability of emulsions, stabilized by LPL, has been attributed to the 
formation of surface-active LPL-protein complexes at droplet interfaces12–15. These complexes 
subsequently prevent the formation of protein-protein interactions in the interfacial layers. As 
discussed earlier, it has generally been accepted that milk fouling is at least a two-step process 
starting with protein deposition on the heat exchanger. Inhibition of protein-protein interactions 
by LPL may therefore lead to a reduction in fouling. Addition of phospholipases to raw milk prior 
to thermal processing may lead to a reduction in fouling by production of LPLs which can act as 
protein stabilizers. 
2.3 GLYCEROPHOSPHOLIPID CHOLESTEROL ACYLTRANSFERASE 
2.3.1 The use of glycerophospholipid cholesterol acyltransferase in the dairy industry 
Since protein fouling is the major step during heat induced fouling, it is conceivable that a 
reduction in protein fouling would result in an overall reduction of the fouling rate. Members of 
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the genus Aeromonadaceae (formerly Vibrionaceae) produce a surface active enzyme, 
glycerophospholipid cholesterol acyltransferase (GCAT), which shares similarity with members 
of the lipase family of enzymes. As described earlier, heat denaturation and protein-protein 
complex formation of β-lactoglobulin have been considered to be the rate limiting step in fouling 
during thermal processing of dairy products 3,21. Treatment of raw milk with GCAT, prior to UHT 
treatment, results in the conversion of native milk phospholipids to yield surface active LPLs 
and, either free fatty acids or cholesteryl esters depending on the absence or presence of 
cholesterol. The formed LPLs subsequently associate with β-lactoglobulin and caseins, 
increasing their heat stability. This increase in stability results in a reduction of free activated β-
lactoglobulin. The stabilization of activated β-lactoglobulin effectively removes the main fouling 
substrate, reducing the rate of fouling. 
2.3.2 Origin of GCAT 
Throughout history the genus Aeromonas have gained much notoriety as pathogen of both cold- 
and warm- blooded organisms. Motile Aeromonas species are responsible for large losses in 
fish raised in ponds and reticulating systems. Members of this genus have furthermore been 
indicated as a common contaminant of a variety of raw foods43. The genus Aeromonas was first 
proposed in 1936 Kluyver and Van Niel44 to accommodate a family of enteric bacterium-like 
microorganisms that are ubiquitous in aquatic environments and have polar flagella in the motile 
form45,46. The current description includes the characteristics of being gram negative, non-spore-
forming, facultative anaerobic rods which are catalase and oxidase positive and metabolize 
carbohydrates fermentatively 45,47–50. Aeromonas spp. can be subdivided into mesophilic motile 
and psychrophilic non-motile species. Organisms of the former group include A. hydrophila, A. 
caviae, A. sorbia, A. veronii and A. schubertii which have a single polar flagellum and are 
commonly found in warm water environments (between 5-41 °C). The latter group is clustered 
around A. salmonicida which is more common in colder environments with temperatures 
ranging from 5-25 °C43,45,47,51. 
Aeromonads are among the most common waterborne bacteria in the world, frequently causing 
disease among aquatic organisms including fish, frogs, turtles and alligators and have recently 
been considered as emerging human pathogens47,52. Mesophilic species of Aeromonas have 
been associated with a wide range of human infections of which gastroenteritis is the most 
common53. Members of the psychrophilic group are not human pathogens since these 
organisms are not able to survive at temperatures in excess of 25°C. They, however, are 
responsible for considerable losses in feral and cultured fish47. It is important to note that 
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although Aeromonads are major fish pathogens, they form part of the normal intestinal 
microflora of healthy fish47. The mere presence of Aeromonads is therefore not an indication of 
disease. The pathogenicity of these organisms are related to physiological and environmental 
stresses which are most commonly associated with fish under intensive culture47. For this 
reason, high mortality rates are often observed in cultured fish. 
Historically Aeromonas species have been designated to the eubacterial family Vibrionaceae 
based primarily on phenotypic expression45,46,50,52,54. As a result, since creation of the genus 
Aeromonas, classification of organisms to this family has been in a state of flux, often leading to 
confusion and controversy. Definition of the exact taxonomic position of Aeromonas species has 
previously been difficult. These organisms share several phenotypic properties defined to be 
characteristic of each of the two eubacterial families, the Vibrionaceae and 
Enterobacteriaceae46. However, Colwell et al.46 provided substantial molecular genetic evidence 
indicating that Aeromonas have a sufficiently distinct phylogenetic history from the 
aforementioned eubacterial families to warrant exclusion from the family Vibrionaceae. These 
authors subsequently proposed a distinct new family of eubacteria, the Aeromonadaceae, to 
accommodate Aeromonads.   
2.3.3 Extracellular products of Aeromonads 
Aeromonas species produce various extracellular products (ECP) that contribute to the 
pathogenicity and virulence of these organisms45,51,55. The ECPs have been shown to consists 
of a wide array of enzymes that actively degrade a variety of complex protein, polysaccharide, 
mucopolysaccharide, and lipid-containing molecules49,55. Characterization of the ECPs from 
Aeromonas indicated that the primary toxins produced are proteases, haemolysins, 
leukocytolysins, cytotoxins, lipases and the weak haemolysin, GCAT51,56–58. Virulent strains of  
A. salmonicida produce a further virulence factor, the surface layer (S layer), in addition to the 
ECPs59–63. The S layer, originally known as the additional layer (A layer), is a supplementary 
layer external to the outer membrane composed of a tetragonally arrayed protein of 50 kDa (A-
protein). The S layer is tethered to the cell surface by lipopolysaccharide55,61,63–65. It was argued 
that this layer is a principle virulence factor of A. salmonicida, since mutants lacking the S-layer 
are avirulent64. The exact role of the S-layer is not yet fully understood, however, it has been 
hypothesized that this layer may be involved in protection, molecular sieving, cell adhesion, 
surface recognition, morphogenesis and autoaggregation60. Autoaggregation is considered 
essential for virulence59,60,66. Loss of the S layer results in the loss of the ability to autoaggregate 
along with a concurrent attenuation in virulence, although at least moderate virulence may be 
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retained in non-autoaggregating strains59,63. The S layer is furthermore thought to physically 
protect cells against bacteriophages since cells exhibit phage sensitivity in the absence of the S 
layer61,66.  
A. salmonicida is the causative agent of furunculosis, a septicemic salmonid disease 
characterized by necrotic lesions and general liquefaction of internal tissues67. The ECPs 
produced by A. salmonicida contains a cocktail of potential toxins. Munro and co-workers68 
showed that when a total ECP preparation from A. salmonicida was intraperitoneally injected, all 
the symptoms characteristic of furunculosis could  be reproduced. This observation prompted a 
search for the major ECP toxin(s). Since the necrotic lesions characteristic of furunculosis are 
proteolytic in nature, it was argued that the major toxin would most likely be a protease. Ellis et 
al.69 subsequently isolated a single 70 kDa serine protease which was injected intramuscularly 
into juvenile Atlantic salmon. The result was compared with a total unfractionated ECP 
preparation with similar proteolytic activity. Interestingly, the injection of purified protease 
yielded significantly reduced necrosis when compared to the unfractionated ECP preparation. 
These results indicate that other toxins are important for virulence, or that other ECP enzymes 
act synergistically with the protease to produce the characteristic symptoms of furunculosis. 
Various authors subsequently showed that a mixture of purified protease and haemolysin 
(GCAT), termed T lysin by Titbal and Munn70, was as efficient in producing muscle lesions in 
rainbow trout and Atlantic salmon as whole ECP59,71,72. Supportive of such a synergistic 
mechanism, it was observed that purified haemolysin incompletely lyses erythrocytes, only in 
the absence of protease59. Since intramuscular injection of a cocktail of protease and GCAT 
yielded the characteristic symptoms of furunculosis, it was argued that these enzymes are the 
major virulence factors produced in the ECPs of A. salmonicida.   
Bernheimer et al.73 was the first to described the hemolytic effect of ECPs from Aeromonads 
when they showed the presence of phospholipase- A and C activities in the ECPs from  
A. hydrophila. MacIntyre and Buckley74 subsequently indicated that filtered supernatants of  
A. hydrophila had the ability to produce free fatty acids, cholesterol esters, and deacylated 
water-soluble products when incubated with erythrocyte membrane glycerophospholipids. This 
activity was initially attributed to a high molecular weight enzyme complex between GCAT and 
the phospholipases described by Bernheimer et al.74,75. However, it was subsequently revealed 
that all the reactions are catalyzed by the single GCAT enzyme which exhibit phospholipase, 
acyltransferase and lysophospholipase activity76.  In the native state GCAT forms a complex 
with lipopolysaccharide (LPS) and acts as a heamolysin, leukocytolysin and a cytotoxin56. 
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The role of the 70 kDa serine protease and GCAT-LPS as major virulence factors was, 
however, discounted when Vipond and co-workers67 showed, with the use of defined deletion 
mutants, that neither the protease nor GCAT is essential for the development of diseases. It 
was subsequently proposed that the activity of the serine protease may play a role in activation 
of protoxins, in particular GCAT (will be discussed later), in addition to tissue destruction at the 
site of infection67. GCAT, on the other hand, is able to transfer an acyl chain to various straight 
chain alcohols77. Since it was consistently observed that acyl transfer is maximal when 
cholesterol is the acceptor, it implies that the in vivo function of GCAT is not in cellular 
metabolism, as Aeromonas do not contain cholesterol77,78. It is therefore more likely that GCAT 
serves an accessory role during infection rather than cellular metabolism by enhancing nutrient 
acquisition and cell proliferation by providing essential amino acids needed for growth 67,79. 
Consequently, it was concluded that although these enzymes are not solely responsible, in 
combination with other ECP enzymes, they aid in the progression of furunculosis. 
Although the role of GCAT as a major virulence factor during infection was discounted, the 
multiple reactions catalyzed by this enzyme attracted considerable attention for its 
biotechnological application65. The ensuing review will describe the molecular characteristics of 
GCAT.  
2.3.4 Glycerophospholipid cholesterol acyltransferase 
Early speculation that GCAT may contribute to the pathogenicity of A. salmonicida led Macintyre 
and co-workers to conduct a study to determine the extent of this enzyme‟s distribution in, the 
then family, Vibrionaceae57. Through these studies it was shown that all organisms of this 
family, with the exception of P.shigelloides, are able to produce cholesterol esters and LPL 
when egg yolk emulsions or human erythrocyte membranes are used as substrates. 
Interestingly, of all organisms examined, Staphylococcus aureus was the only organism of 
another family which showed GCAT activity on the same substrates. Prior to these studies the 
activity of GCAT was proposed to be that of an enzyme complex between an acyltransferase 
and a lipase. The report by Macintyre et al.57 was the first instance where these activities were 
attributed to a single enzyme catalyzing multiple reactions. 
The GCAT enzyme (EC 2.3.1.43), produced by all members of the Aeromonadaceae, is a  
≈ 25 kDa enzyme that forms a complex with LPS, the complex having an estimated molecular 
mass of 2000 kDa 48,56. Formation of this complex has a stabilizing effect on the GCAT enzyme, 
and protects the enzyme from inactivation by heat and proteolytic degradation48,49,56. 
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Additionally, complex formation enhances the hemolytic activity and lethal toxicity eightfold56. 
The lipase activity of GCAT is, however, unaffected by complex formation with LPS56. Lee56 
proposed that complex formation with LPS may enhance the hemolytic activity of GCAT by 
aiding in membrane penetration, delivering the enzyme to the site where optimal substrates are 
present. Once inside the fish host, GCAT completely lyses its erythrocyte membranes56,80,81. 
Conversely, the enzyme is not able to lyse human erythrocytes. The phospholipid makeup of 
erythrocyte membranes therefore play a significant role during hemolysis 48,77. The substrate 
specificity of GCAT will be discussed in more detail in the ensuing sections. 
GCAT shares several features with the mammalian plasma enzyme lecithin:cholesterol 
acyltransferase (LCAT)82,83. As with LCAT, GCAT catalyzes the position 2 specific transfer of an 
acyl chain from a phospholipid donor to a suitable acceptor77,84. Like the mammalian enzyme, 
GCAT has no divalent cation requirement and its activity is stimulated by apolipoprotein A-176,77. 
However, GCAT has far less stringent phospholipase substrate requirements than LCAT as all 
commonly occurring glycerophospholipids can function as substrates77,78. Based on the 
similarities with the mammalian plasma protein, and because it is far more stable, GCAT have 
received considerable attention, not only as a research tool, but also for its potential 
biotechnological applications65.  
2.3.4.1 Purification of GCAT 
In order to study the function and mode of action of enzymes, large quantities of pure protein is 
needed. The purification of native GCAT from A. salmonicida is cumbersome, involving a 
complicated multistep purification procedure which ultimately yields small amounts of pure 
enzyme65,76. A recombinant method was therefore pursued. In 1990 Hilton and coworkers65 
described a method wherein large quantities of recombinant GCAT, from A. hydrophila, can be 
expressed in a mutant A. salmonicida host65. Selection of this mutant was based on the 
production of greatly reduced amounts of its own extracellular proteins in addition to reduced 
amounts of chromosomally encoded GCAT. Extracellular expression of recombinant GCAT can 
be induced with isopropyl β-D-thiogalactoside (IPTG), enabling enzyme purification from cell 
free culture supernatant by ammonium sulfate precipitation, centrifugation and successive gel 
filtration and ion exchange chromatography steps65. Ammonium sulfate precipitation recovers 
the enzyme bound to the outer membrane fragments from cell free culture supernatants. These 
fractions contain a small number of proteins resulting in a dramatic increase in specific enzyme 
activity76. GCAT can subsequently be selectively recovered by detergent solubilization and 
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centrifugation. This method typically yields 35-45 mg of pure GCAT from 2 L culture supernatant 
as compared to 1-2 mg pure protein from 3.6 L culture supernatant for native GCAT65,76.  
The use of GCAT in food products has recently received considerable attention due to the 
stabilizing effect that LPL can deliver to foodstuffs. Although A. salmonicida is not a human 
pathogen, this organism cannot be used as an expression host due to the risk of contaminating 
food products. In lieu of this, a modified form of GCAT from A. salmonicida has been 
successfully expressed in Bacillus licheniformis85. The gene encoding GCAT has been modified 
at a single amino acid, asparagine 80, for improved expression by this host. B. licheniformis is 
considered a class 1 contaminant agent under the NIH guidelines for research involving 
recombinant DNA technology and the use of such expression products are deemed safe for use 
in food products86. This host is furthermore generally regarded as safe (GRAS) and meets the 
criteria for a safe production organism85. Additionally, the host B.licheniformis (BRA7) has been 
modified, by GENENCOR®, to eliminate the production of several enzyme activities, protease 
and amylase, which could impede expression and/or purification85. Recombinant GCAT could 
thus be prepared in large quantities by submerged fed-batch culture fermentation followed by 
the same purification procedures as described above. 
Interestingly, when GCAT is expressed in E. coli, no enzyme could be detected in the culture 
supernatant indicating that the enzyme is not secreted by this host. Similar observations were 
made with a variety of extracellular proteins, leading to the conclusion that E. coli does not 
poses the mechanistic ability for export of these proteins over the cell outer membrane87. 
2.3.5 GCAT genetics 
2.3.5.1 Primary structure 
 Although A. salmonicida is a well-known pathogen of various aquatic organisms, most interest 
has been concentrated on the virulence factors of A. hydrophila. This is mainly because this 
organism is increasingly implicated in clinical human infections45. Most of the original enzymatic 
characterization was therefore focused on GCAT produced by A. hydrophila. There are, 
however, differences between the enzymes produced by these organisms although they 
catalyze similar reactions. The enzyme produced by A. salmonicida is smaller than that of  
A. hydrophila. However, polyclonal antibodies prepared against A. salmonicida GCAT do not 
cross-react with the enzyme produced by A. hydrophila, indicating significant difference 
between these two enzymes87. This observation, however, is difficult to explain since these 
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enzymes share 100% homology in antigenic regions of the polypeptide88. Apart from this, the 
enzymes share 93.7% homology in amino acid sequence88. From Figure 2.2 it can be seen that 
nine out of 21 non-identical residues are located within a region coding for 29 amino acids 
(residues 239-268 highlighted in yellow)88. Excluding this region, homology is 96.1%. The 
enzymes produced by these two organisms therefore compare well on a molecular level. The 
proposed active site residues remain conserved. 
The primary structure of GCAT from A. hydrophila was first published in 1988 by Thornton et 
al.87. The open reading frame encodes a 281 amino acid protein, preceded by an 18 amino acid 
signal peptide, with a predicted molecular weight of 31 303 Da87. This , however, did not 
correlate with results obtained from SDS-PAGE analysis which indicated a molecular weight of 
approximately 35 kDa65,87. Subsequent studies revealed that an error was made in the first 
publication by Thornton et al.65. The error was found to be due to an error in reading frame 
translation. The corrected sequence, presented in Figure 2.2, encodes a protein of 35.1 kDa 
which correlates with the results from SDS-PAGE analysis of purified unprocessed GCAT65.  
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Figure 2.2 Comparison between the primary amino acid sequences of GCAT from A. salmonicida and A. hydrophila 
During purification, the enzyme is reduced in size from 35 to 27 kDa. It was consequently 
suggested that, as with the hole forming protein aerolysin, the enzyme is secreted as a protoxin 
which may undergo post-translational modifications89. In support of this, trypsin treatment of the 
35 kDa protein results in the formation of a protein with a molecular weight of 27 kDa as 
determined by SDS-PAGE. Once formed, the 27 kDa protein is resistant to further degradation, 
except when proteinase K is used. Two separate trypsin digestion sites were subsequently 
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identified (Figure 2.3). Trypsin treatment nicks the enzyme between two cysteine residues 
(cys225 and cys281) resulting in the loss of a 3.7 kDa peptide located towards the C-terminal of 
the protein 83. This yields two protein fragments, a 27 kDa fragment connected to a 4.7 kDa 
peptide via a disulfide bond. 
 
Figure 2.3. Trypsin cleavage sites in GCAT resulting in the loss of the the peptide encoded by amino acids 230 – 




Hilton et al.65 showed that, when trypsinized GCAT is treated with SDS-PAGE sample buffer 
containing mercaptoethanol, the protein migrates as a band of 27 kDa. However, after staining 
with Coomassie Blue, smaller peptides were observed at the front of the gel. Omitting 
mercaptoethanol from the sample buffer results in the migration of a single band corresponding 
to the combined sizes of the 27 kDa protein and the 4.7 kDa peptide, predicted to be produced 
from the second trypsin digestion site65. It was therefore concluded that since mercaptoethanol 
treatment yields two protein fragments, the two cysteines in GCAT are most likely joined by a 
disulfide bond, tethering the 4.7 kDa peptide to the rest of the protein65. 
Formation of the 27 kDa protein, tethered to the 4.7 kDa peptide via a disulfide bond, coincides 
with an increase in enzyme activity, suggesting that, under normal circumstances, GCAT is 
secreted from the host as an inactive pro-enzyme which is post transnationally activated by 
limited proteolysis65. Post-translational activation is therefore most likely a protection 
mechanism wherein the bacteria‟s own membranes are protected from self-inflicted damage 
during secretion65,83. Supportive of this, unprocessed GCAT is not able to penetrate lipid 
monolayers at surface pressures exceeding 20 mN/m whereas after trypsination it is able to 
degrade monolayers at pressures exceeding 40 mN/m65. Studies have shown that the surface 
pressures of natural membranes are approximately 30 mN/m 90. GCAT is thus not able to 
penetrate membranes in the inactive, unprocessed form.  
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Trypsin treatment permits removal of the 3.7 kDa peptide enabling disulfide bridge formation 
between Cys225 and Cys281. Earlier reports suggested that a disulfide bridge may be essential 
for enzyme activity and secretion of lipases91,92. It was furthermore reported that cysteine 
residues may play a role during enzyme catalysis in the human plasma protein LCAT92. Based 
on these reports, the role of cysteine residues during GCAT activity and secretion was 
investigated. GCAT contains a single pair of cysteine residues that form a disulfide bond. Site-
directed mutagenesis of these residues indicated that the major role of the disulfide bond is to 
stabilize the three dimensional structure of the protein83. In the absence of the disulfide bond the 
protein is more susceptible to urea denaturation and degradation by proteases, along with a 
significant reduction in enzymatic activity. The reason for the reduction in enzymatic activity will 
become evident in the following section. The absence of the disulfide bond may permit the 4.7 
kDa peptide to move away from the 27 kDa fragment, thereby exposing previously hidden sites 
to proteases83. 
2.3.5.1 Homology of GCAT with other enzymes 
Initially the primary structure of GCAT was elucidated to determine the sequence similarities 
with the mammalian plasma enzyme, LCAT. Surprisingly, although these two enzymes catalyze 
similar reactions they differ considerably in primary structure. Sequence similarities are, 
however, reported among members of the lipase superfamily87,93,94. GCAT contains a sequence 
which is highly conserved in lipase enzymes from various host organisms. Based on data 
obtained from porcine pancreatic lipase, this region is believed to form the interfacial lipid-
binding site of lipases87. Additionally, GCAT contains a second sequence which shares 
homology with the suggested active site87. Interestingly, Thornton et al.87 showed that although 
the apparent sequence homology between the proposed active site of GCAT and that of 
pancreatic lipase is not convincing (Figure 2.4), this region is more homologous than that of the 
same sequence of LCAT. The same authors furthermore showed that both GCAT and 
pancreatic lipase are insensitive to levels of diisopropylphosphofluoridate that would render 
LCAT completely inactive. These results indicate alternative roles for the active site serine of 
these two enzymes.  
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2.3.5.2 The active site residues 
Evolution of the primary structure of proteins is constrained by its function. Based on the 
coevolution of protein primary structure and function, homologous proteins from diverse sources 
can often be grouped in families founded on the conservation of vital amino acid sequences95. 
The apparent similarity between the active site of GCAT and pancreatic lipase suggests that 
GCAT may be part of the lipase family of enzymes. In support of this, GCAT acts as a 
phospholipase when no acyl acceptor is available. The active site of lipases typically contains a 
conserved catalytic triad consisting of serine, aspartic acid and histidine96. In order to confirm if 
GCAT is indeed a member of the lipase family, the active site residues were determined. 
The active site serine of lipases is contained in a small consensus region with the conserved 
sequence G-X-S-X-G40. This sequence is also conserved in members of other esterase families, 
including the serine proteases40,97,98. Data obtained from a range of chemical inactivation 
experiments proposed that the active site of GCAT, like serine proteases, consists of a Ser-His-
Asp catalytic triad40,99,100. Hilton and Buckley40 showed that Ser16 is essential for the activity of 
GCAT. Chemical modification of this residue results in total loss of enzyme activity. In lipases 
with known three dimensional structures the G-X-S-X-G sequence, which contains the active 
site serine, forms a critically important loop between an α-helix and a β-sheet96. In GCAT 
however, Ser16 is located in the sequence G-X-S-X-S40,96. The active site consensus is 
furthermore located in close proximity to the amino terminus which is in contrast to lipase 
enzymes wherein the active site is located closer to the middle of the protein96,101. Thus, 
although GCAT shares several features with lipases, this enzyme is different from lipases in the 
location of the active site serine. 
Suggested active site 
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All lipases with known primary structures have at least two hydrophobic amino acids preceding 
the G-X-S active site consensus sequence102. To determine the role of these residues in 
catalysis, they were mutated by site-directed mutagenesis102. During these studies Phe13 was 
changed to a Ser in addition to mutation of the second serine following the active site serine to 
glycine. For comparative purposes this serine was also mutated to valine. These mutations not 
only decreased enzyme activity, but also resulted in a decreased secretion from the host 
organism. This is an indication that these residues may play a pivotal role in the correct folding 
and/or secretion of GCAT. Surprisingly, although mutation of the serine following the active site 
serine to a glycine brings the sequence into line with the lipase consensus, mutation resulted in 
an inactive enzyme. These results indicated the presence of at least two groups of lipolytic 
serine esterases. The latter group being one in which the active site serine is contained within 
the active site consensus G-X-S-X-S. 
The observation that an inactive enzyme is obtained, when the second serine in the active site 
consensus of GCAT is mutated, led Upton and Buckley101 to determine the extent of distribution 
of the G-X-S-X-S consensus in other enzymes102. Based on a BLAST search focused on short, 
highly conserved protein segments, it was found that seven other proteins have identical or very 
similar sequences. The consensus sequence for this region is FGDSLS preceded by three 
hydrophobic amino acids101. Evidence obtained from thioesterase I, produced by E.coli, and 
arylesterase, from Vibrio mimicus, suggests that the first serine in the consensus region is most 
likely the active site nucleophile as is the case in GCAT 101,103. It was furthermore shown that all 
eight enzymes have at least four other “sequence blocks” in common which appear in the same 
order in each case. These observations provided evidence that the abovementioned enzymes 
represent a new family, or subfamily, of lipolytic enzymes. Discovery of the sequence blocks 
provided clues to the locations of the other active site residues which, at the time of publication, 
were not known for any of the enzymes. 
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Figure 2.5. Protein sequence homology blocks as proposed by Upton and Buckley
101
. Each block compares 
potentially important amino acids in GCAT with other proteins possessing a G-X-S-X-S active site motif. The numbers 
in brackets are an indication of the number of amino acid residues between conserved blocks.   
In 1996 Brumlik and Buckley96 attempted to identify the active site histidine and aspartic acid 
residues by using the sequence homology blocks described above. The authors proposed that, 
for enzymes with similar catalytic activities, the active-site residues should be contained within 
the same sequence blocks. This assumption proved true as it was shown that the active-site 
serine, Ser16, is located in block I in the conserved consensus, FGDSLS, described earlier.  
GCAT contains 5 histidine residues of which only two are located in the 27 kDa protein 
fragment. Since it has previously been shown that the 27 kDa fragment retains activity after 
removal of the 4.7 kDa fragment, Hilton and Buckley40 argued that only His175 and His180 can 
play a role in catalysis. Subsequent site-directed mutagenesis of His175 and His180 to asparagine 
yielded an active enzyme. In agreement with this, it was previously indicated that histidine is not 
required for the catalytic activity of pancreatic lipase, nor hepatic lipase 30,32. These findings led 
to the assumption that histidine does not play a role during catalysis, distinguishing GCAT from 
other lipases40. However, this assumption was disproved upon further inspection of the data 
shown in Figure 2.5. In all the proteins sequences shown in Figure 2.5, block v is the only block 
that contains histidine, implicating this histidine, His291 in GCAT, the most likely candidate for a 
role during catalysis as the remaining histidines are not found in conserved regions96. Brumlik 
and Buckley96 showed that although the enzyme is secreted at normal levels, a completely 
inactive enzyme is obtained when His291, located in the 4.7 kDa peptide, is replaced with 
asparagine. This finding is in contrast to a previous finding that enzyme activity is retained after 
removal of the 4.7 kDa fragment65. These authors subsequently suggested that refolding of the 
27 kDa peptide most probably gave rise to a structure that had residual lipase activity 40. 
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Identification of the active site aspartic acid proved challenging since mutation of various 
aspartic acid residues not only resulted in reduced activity, but also reduced secretion to such 
an extent that sufficient protein could not be obtained for activity studies. Identification of the 
active site aspartic acid was therefore not possible without the sequence information gained 
from Figure 2.5. In Figure 2.5 the only blocks which contain aspartate residues in all the proteins 
are blocks I and III. The aspartate residues, Asp15 and Asp116 in GCAT, was thus the most likely 
to play a role in catalysis96. The role of each aspartate residue was subsequently determined by 
individual mutation of each residue. GCAT contains additional aspartate residues in blocks IV 
and V. Asp157 and Asp228 were thus also mutated to asparagines96. It was subsequently 
determined, by a process of elimination, that Asp116 is the most likely candidate for a role in 
catalysis since Asp116 is, not only the only aspartate residue conserved in the same block as all 
the other proteins, but this residue is also correctly positioned between the catalytic serine and 
histidine96. Mutation of this residue ultimately resulted in total enzyme inactivation. 
Since the active site catalytic triad has been established, the role of other amino acid residues in 
catalysis was investigated. It was briefly discussed previously that the hydrophobic amino acid 
residues preceding the active site serine may be essential during the protein folding or 
secretion. Robertson et al.102 attempted to determine if tyrosine plays a role in protein folding 
and/or secretion from the host cell. For this purpose, the authors nitrated the possible reactive 
tyrosine residues with tetranitromethane. Nitration of tyrosine resulted in an 80% loss in activity. 
The reactive tyrosyl residues were identified after treatment with cyanogen bromide and 
subsequent high performance liquid chromatographic (HPLC) analysis of the resulting peptides. 
Three fractions were found to contain reactive nitrated tyrosyl residues, although only two of the 
three nitrated residues could be detected by HPLC. The remaining residue was identified by 
sequencing the amino terminus containing the remaining possible reactive residue. In this 
fragment Tyr30 was shown to be nitrated. Based on the results obtained, the above residues 
were replaced with phenylalanine residues by site-directed mutagenesis. It was subsequently 
shown that Tyr230 is responsible for the loss in activity, since mutations of the other residues did 
not affect enzyme activity considerably102.  
The reduction in activity was specific for substrates consisting of phospholipids since the 
reaction rate was not as severely affected when p-nitrophenyl butyrate was used as substrate. 
From this data it can be deduced that GCAT interacts with these substrates in different 
manners. Furthermore, tetranitromethane treatment of the mutant, wherein Tyr230 was mutated, 
did not result in additional reduction in activity. The results thus indicated that, although mutation 
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of Tyr230 affects the activity of GCAT when phospholipids are used as substrates, this residue is 
not essential to the activity of GCAT since the reaction rate is unimpaired when p-nitrophenyl 
butyrate is used as substrate. The authors105 concluded that Tyr230 most probably interacts with 
the carbonyl at the 2-position of the phospholipid and is thus essential during phospholipid 
binding in the substrate binding sites. 
2.3.6 Catalytic activity and substrate specificity 
As previously discussed, GCAT shares several features with lipases. The GCAT enzyme 
produced by Aeromonads, like lipases, is activated at lipid-water interfaces, have relatively non-
specific esterase activity and does not require calcium as co-factor 65,102. Although this enzyme 
will catalyze the hydrolysis of neutral- and phospholipids, it is distinguished from other lipases 
by the unusual ability to specifically carry out acyl transfer from the 2-position of phospholipids 
in the presence of a suitable acceptor such as cholesterol 83,96. When no acceptor is available, 
the enzyme exhibits phospholipase A2 (EC 3.1.1.4) activity
76. GCAT will furthermore catalyze 
the hydrolysis of LPL and cholesteryl esters (EC 3.1.1.5) when no phospholipids are available. 
However, transacylation of 1-acyl-lysophosphatidylcholine is not catalyzed, leading to the 
conclusion that a specific interaction between the acyl donor and acceptor is needed for 
acyltransferase activity 78,106. The main reactions catalyzed by GCAT are depicted in Figure 2.6. 
 
Figure 2.6. Reactions catalyzed by GCAT. A; Esterification of cholesterol with a fatty acyl chain from a phospholipid 
donor. B; Phospholipid hydrolysis by the lipase activity of GCAT in the absence of a suitable acceptor
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Buckley77 observed that, although GCAT has no absolute requirement for specific phospholipids 




chain or unsaturated fatty acids. In experiments with fish and human erythrocytes as substrates, 
it was shown that the enzyme effectively lyses fish erythrocytes. However, incubation with 
human erythrocytes resulted in incomplete lysis, although hydrolysis and transacylation of the 
membrane phospholipids still occurred56. This is due to difference in membrane phospholipid 
makeup of fish and human erythrocytes. It has been established that fish tissues are much 
richer in polyunsaturated fatty acids and, additionally, the phosphatidylcholine content of 
erythrocyte membranes are about 30% higher than in human erythrocytes56. GCAT is thus well 
suited to digestion of fish tissues during A. salmonicida infection. 
In contrast to the nonspecific requirements of acyl chain donors, GCAT displays considerable 
specificity toward acyl acceptors. Although a variety of alcohols can act as acyl acceptors, 
preference is shown toward steroids with 3βOH-groups and trans A:B rings, with cholesterol 
being the most preferred acceptor40,77,78,106. Steroids with 3αOH-groups and planar A:B rings do 
not act as acceptors, but as inhibitors of acyl transfer77. It was therefore argued that a hydrogen 
bond between a donor and acyl acceptor is a minimum requirement for enzyme-catalyzed acyl 
transfer77,106. When the donor is hydrogen-bonded to water, simple hydrolysis of the ester 
occurs77,106. Buckley77 subsequently suggested that cholesterol is a good acceptor because it is 
able to interact maximally with the donor through van der Waals interactions, enabling the 
formation of the hydrogen bond. Molecules containing 3αOH-groups or puckered ring systems 
inhibit hydrolysis, and acyl transfer, by interacting with the acyl donor in the enzyme pocket. 
However, because the molecule is not oriented correctly, hydrogen bond formation is not 
possible77. This mechanism of inhibition effectively removes the enzyme substrates, and 
occupies the enzyme catalytic site. 
While attempting to assess whether the glycerophospholipid backbone is an absolute 
requirement for enzymatic hydrolysis, Buckley78 found that GCAT catalyzes the hydrolysis of 
synthetic p-nitrophenyl ester substrates. These substrates were also effective acyl donors for 
the enzyme-catalyzed esterification of cholesterol78. In experiments using p-nitrophenyl butyrate 
it was found that the apparent Vmax values are similar to those obtained using phospholipid 
substrates, although this data was not published78 . Nitrophenyl esters are valuable tools for 
kinetic studies of the enzyme, although a comparison between the kinetic parameters, Km and 
Vmax, is essential in order to rationalize the results obtained. 
Results from studies using nitrophenyl substrates indicated that GCAT is a nonspecific esterase 
which preferentially catalyzes acyl transfer in the presence of a suitable acceptor78. In contrast 
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to the lack in specificity displayed by the use of nitrophenyl substrates, acyl transfer to 
cholesterol is specific to the 2-position when a phospholipid is the acyl donor76–78. It was 
subsequently proposed that the positional specificity is based on the saturated fatty acid 
preferences of GCAT78. Buckley78 examined this possibility by comparing the enzyme‟s action 
on 1-plamitoyl-2-oleoyl-phosphatidylcholine and on 1-oleoyl-2-palmitoyl-phosphatidylcholine. 
The results of these studies confirmed that acyl transfer is 2-position specific as more than 80% 
of the fatty acid transferred to cholesterol was oleate, when 1-plamitoyl-2-oleoyl-
phosphatidylcholine was used, and more than 80% was palmitate when the latter phospholipid 
was used 78. The acyltransferase activity of GCAT is thus not dependent on the fatty acid 
preference since acyl chain saturation had no effect on the transferase activity. These results 
confirmed that a specific interaction between acyl donor and acceptor is essential for acyl 
transfer. 
The mammalian plasma protein LCAT catalyzes similar reactions as GCAT. However, these 
enzymes differ based on the acyl donor preference. Additionally, LCAT has an absolute 
requirement for the activator, apolipoprotein A-1 (Apo-A1)76. LCAT activity can furthermore be 
activated by the presence of albumin. Although GCAT has no co-factor or activator 
requirements, it has been reported that enzyme activity is augmented in the presence of both 
albumin and apolipoprotein A176,108. Albumin most likely activates the enzyme by complex 
formation with lysolecithin and fatty acids whereas Apo-A-I interacts selectively with the surface 
of liposome substrates76. Although both enzymes catalyze the acylation of cholesterol, when a 
suitable acyl donor is present, these enzymes differ based on the optimal 
cholesterol/phospholipid ratios. Cholesterol ester production by LCAT is maximal at 
cholesterol/phospholipid ratios of 1:3, 1:4, 1:6 or 1:7 with Apo-A1 present, whereas GCAT 
activity have been shown to be maximal with liposomes consisting of cholesterol/phospholipid in 
1:1 ratio76. The mammalian enzyme can catalyze the acylation of lysolecithin by a mechanism 
requiring low density lipoprotein, while the bacterial enzyme catalyzes only the hydrolysis of 
LPL76,109. The lysophospholipase activity of GCAT is only active when no other substrates are 
available. 
2.3.7 3D protein structure 
The function of proteins in vivo is, to a large degree, determined by its interaction with other 
molecules in its immediate environment. The degree of interaction is dictated by the 3D 
structure of the protein. Elucidation of the 3D structure of a specific protein may therefore yield 
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important information regarding the mechanism of catalysis. The 3D structure of GCAT, 
however, remains to be determined despite recent advances in both experimental techniques 
and computational prediction methods.   
Computational protein structure prediction is based on the conservation of key sequences 
among proteins with similar functions. Homologous proteins can be recognized by primary 
structure comparison with a database of proteins with known structures. However, some 
proteins require chaperones, some are inherently disordered, and some undergo post 
translational modification. Computational prediction cannot accurately predict the effect of post-
translational modification and the effect of chaperones directly from the primary protein 
structure. Since GCAT undergoes post-transnational activation, the loss of a 3.7 kDa peptide, 
and does not share direct homology with other enzyme families, the 3D structure varies greatly 
when different prediction software is used. 
2.3.8 Application of GCAT in the dairy industry 
Since the GCAT enzyme has no specific phospholipid substrate requirements, and does not 
require any co-factors. The versatility and wide range of non-specific substrate requirements 
makes it an ideal candidate for application in the food industry. For these reasons, GCAT has 
been employed as a processing aid during ultra-high temperature processing under the 
commercial name FoodPro® Cleanline (FPCL), developed by DuPont®. Treatment of milk, and 
other dairy products, with FPCL can increase thermal processing efficiency by reducing UHT 
plant fouling. Moreover, the GCAT enzyme is completely inactivated by UHT treatment and it 
has no subsequent technological function in the final product. The use of FPCL in UHT milk 
therefore meets the requirements for classification as a processing aid since: i. it cannot be 
consumed as a food by itself ii. it is intentionally added during processing of raw material to fulfill 
a technological purpose and iii. remains present in the final product without affecting the overall 
milk content110. Milk containing FPCL may therefore be classified as drinking milk without 
additional labeling requirements. 
Other phospholipases may be used to hydrolyze milk phospholipids to LPL, which would act to 
reduce fouling. However, during this reaction, the free fatty acids liberated from phospholipids 
accumulate. Phospholipases do not poses transferase activity which sequester free fatty acids 
as fatty acyl esters such as cholesteryl esters. Free fatty acids are responsible for the rancid, 
unpleasant taste which is often associated with spoilt milk111. Milk with an acid degree value 
(ADV), an indication of potential milk rancidity, of more than 1 (0.25% m/m) is considered rancid 
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and should be discarded112,113. Furthermore, milk contains various inherent and microbial 
lipases which should be inactivated as soon as possible since these enzymes accelerate milk 
spoilage. Consequently, addition of foreign lipases would be counterintuitive. For this reason, 
GCAT is particularly well-suited for use in the dairy industry. 
2.4 CONCLUSION 
The GCAT enzyme produced by Aeromonads is unique in its catalytic activity with plant- and 
animal lipids. Although the mechanism of catalysis has been elucidated, to the best of our 
knowledge, no kinetic parameters for any of the reactions catalyzed by GCAT have been 
published. Surprisingly, various authors have described activity assays whereby the Km and Vmax 
values for this enzyme could be calculated. It therefore appears that these assays are not as 
straight forward as the authors would suggest. Knowledge of the kinetic parameters would 
provide a better understanding of the reaction between GCAT and its substrates.  
Ideally, familiarity with the kinetic parameters, Km and Vmax, would allow for the prediction of 
product formation at a particular GCAT dosage and incubation time. By manipulating the 
dosage and incubation time of GCAT in milk processing, specific characteristics (e.g. final FFA 
and cholesterol concentration) of the product can be altered to meet the demands of the client. 
These advantages, together with the fact that no current kinetic data is available stimulated our 
interest to characterize the GCAT enzyme in terms of its kinetic parameters. It was therefore 
necessary to first evaluate quantification techniques for each of the reaction products in order to 
develop an accurate activity assay. Since the FoodPro® Cleanline preparation will be used in 
the dairy industry, this preparation was used in all subsequent experiments described in this 
thesis.
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CHAPTER 3  
GCAT ACTIVITY MONITORING AND KINETICS 
– A BRIEF OVERVIEW 
3.1 INTRODUCTION  
Phospholipases play a major role in various cellular processes including lipid metabolism, signal 
transduction and host defenses. As a result, this group of enzymes is amongst the world‟s most 
extensively studied enzymes. In recent years, phospholipases, including GCAT, have attracted 
considerable attention as biotechnological tools in various industries including the food, dairy 
detergent, textile, pharmaceutical, cosmetic and fuel industries40,114. For successful industrial 
application a rapid and reliable activity assay is needed in order to evaluate the degree of 
enzymatic lipid hydrolysis and/or ester synthesis. A large number of techniques have been 
described whereby lipolytic activity of enzymes can be determined96,115. However, apart from 
catalyzing the hydrolysis of phospholipids, GCAT preferentially catalyzes acyl transfer in the 
presence of suitable acyl acceptors. In contrast to lipase activity monitoring, determination of 
transferase activity typically involves the use of radiolabeled substrates40,78,116. The use of 
radiolabeled substrates allows for accurate activity monitoring, however, for large scale 
commercial application radioactive waste production is of major concern. Substrate preparation 
for such assays are also time consuming and difficult to reproduce. 
To overcome the difficulties associated with GCAT reaction monitoring with phospholipid 
substrates, various synthetic substrates have been described. However, since enzymes do not 
necessarily react equally with different substrates, kinetic analysis is vital in order to determine 
the validity of newly developed assays by comparison of the kinetic parameters. This chapter 
will describe the current and potential methods for GCAT activity monitoring and kinetic 
characterization for commercial application. 
3.2 AVAILABLE ASSAYS FOR GCAT ACTIVITY MONITORING 
As discussed in Chapter 2, GCAT shares several features with the lipase family of enzymes. As 
such, this enzyme catalyzes the hydrolysis of phospholipids in the absence of an acyl acceptor. 
For the determination of the hydrolytic activity of lipases, numerous assays have been 
described. However, since phospholipids do not possess chromogenic properties, which enable 
continuous reaction monitoring, these assays often rely on the use of subsequent enzymatic 
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reactions which yield a detectable product115,117. When using these methods kinetic analysis can 
only be performed in a discontinuous manner since the quantification of reaction products is 
dependent on subsequent reactions. Although discontinuous assays have several 
advantages118, quantification of hydrophobic reaction products (FFA and cholesteryl esters) 
often require solvent extraction followed by separation and quantification of reaction products 
and substrates. Separation of cholesterol and cholesterol esters can be achieved 
chromatographically, however, detection and quantification is difficult, especially in complex 
media. Various attempts have been made to overcome the difficulties associated with the use of 
lipids as substrates in GCAT assays78. In these methods activity is monitored by either the 
utilization of substrates or product formation when incubated with experimental or synthetic 
substrates. The major lipase assays currently used are listed below. 
3.2.1 Assaying activity by utilization of substrate 
a. Nephelometry – Lipase activity is monitored as a reduction in the absorbance of a 
triacylglycerol emulsion as a function of time. This method is sensitive, but artifacts can 
interfere with activity determination115. 
b. Turbidimetry – Lipolytic activity is measured as the increase in absorbance of a  
Tween 20 solution in the presence of CaCl2. The increase in absorbance is due to the 
release of free fatty acids from Tween 20. The liberated FFAs associate with CaCl2 and 
precipitate causing an increase in absorbance at 500nm119. 
c. Interfacial tensiometry – Enzyme activity is monitored as a reduction in surface tension 
of a lipid suspension as a function of time at an air-water interface. The reduction in 
surface tension is due to the solubilization of lipolytic reaction products. This method is 
highly sensitive, however, it is still unknown if this method is representative of enzyme 
reactions occurring at oil-water interfaces115. 
d. Atomic force microscopy – This method was developed by Nielsen et al.120 and relies 
on real time imaging of the formation of increasingly large defects (holes) in the surface 
of lipid bilayers. The increase in hole area can be recorded as a function of time and 
analyzed by purpose built software. Specific enzyme activity can be calculated as the 
increase in interface hole size as a function of time, assuming that a single enzyme 
molecule is acting at each hole. 
3.2.2 Assaying activity by formation of reaction products   
e. Titrimetry – Titrimetric and indicator dye methods, such as the pH-stat method, are 
generally used as a reference lipase assay121. This method can be used for the 
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quantitative analysis of lipase activity, and is sensitive to within 1µmol of product 
released122. Titrimetry is still used to validate newly developed lipase assays. 
f. Quantification of FFA release – Various methods have been developed for the 
quantification of liberated FFA. These methods often rely on FFA binding to a 
chromogenic dye followed by spectrophotometric detection115,121,123. Enzyme coupled 
FFA assays have also been described. These methods rely on the conversion of FFA 
to their coenzyme A derivatives which can subsequently be oxidized by a chromogenic 
substrate resulting in a colour or fluorescence, depending on the substrate probe 
used124,125. Chromatographic detection has also been described126,127. However, such 
methods separate and detect individual FFAs. For quantification of total FFAs, a 
standard for each individual FFA is needed. Radiolabeled substrates may be used to 
overcome this drawback. 
g. Flourometric assays – These assays often rely on the lipase induced displacement of 
fluorescent fatty acid probes from fatty acid binding proteins115,128. Wolf et al.129 
described a sensitive fluorescent assay using the naturally occurring fluorescent probe 
2-parinaroyllecithin. In this assay, the liberated parinaric acid binds to albumin resulting 
in increased fluorescence intensity which can be quantified as a function of time. 
h. Use of synthetic substrates – In order to overcome the difficulties associated with the 
use of hydrophobic lipid substrates, the use of water soluble nitrophenyl based 
substrates have been described for the assay of lipase enzyme activity130,131. During the 
reaction of lipases with nitrophenol containing fatty acyl substrates, the ester bond is 
hydrolyzed to yield chromogenic nitrophenol and a fatty acid. This reaction will be 
discussed in more detail in section 3.4.3.  
Upon comparison of the different assay methods Vorderwulbecke et al.132 indicated that no 
universal lipase assay exist115. This is mainly because lipases, although often very similar, 
regularly differ dramatically in terms of enzymatic activity and substrate preference. No single 
assay can accurately quantify the hydrolytic activity of all lipases. Furthermore, although the 
abovementioned assay systems may be used to determine the lipolytic activity of lipase 
enzymes, they cannot monitor the transferase reaction catalyzed by GCAT since no acyl 
acceptor is available. For this reason lipase assays have been adapted to incorporate suitable 
acyl acceptors for GCAT catalysis. The use of such assays have also been described and relies 
on the use of experimental lipid membranes impregnated with cholesterol as acyl 
aceptor39,40,76,78. During these studies, the use of synthetic nitrophenol containing fatty acyl 
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substrates was also investigated. It has been hinted that reaction rates obtained from assays 
using egg yolk lecithin and para-nitrophenol butyrate (pNPB) are similar, although this data was 
never published78. Since the use of pNPB would enable continuous GCAT reaction monitoring, 
it would be of interest to investigate this possibility further. 
3.3 GCAT ACTIVITY MONITORING  
3.3.1 Shortcomings of the current method of GCAT activity screening 
As mentioned briefly in the preceding sections, high throughput activity screening is essential for 
the successful industrial application of enzymes. Although some of the assays described in 
Sections 3.2.1 and 3.2.2 can be applied to accurately quantify GCAT activity in commercial 
enzyme preparations, these methods are labour intensive, time consuming and require skilled 
personnel. These methods are furthermore not automatable and often require expensive 
specialized equipment. For these reasons the enzyme activity of the commercial GCAT 
preparation, namely FoodPro® Cleanline, is only determined at central distribution posts in 
Europe, Asia and the U.S.A prior to shipment to the client. The current method of activity 
monitoring relies on the comparison of FPCL activity to an activity standard range prepared from 
a GCAT stock with known activity. This assay is performed in an endpoint styled comparative 
assay wherein the samples with unknown activity is incubated with the activity standards for 
exactly 10 min. Following incubation, the FFA content of each sample is quantified using the 
NEFA HR FFA quantification kit. Although this method is fully automated and eliminates some 
of the difficulties experienced with other assays, such as a need for enzyme inactivation, this is 
not the most appropriate assay available. Because enzyme activity is quantified by comparison 
to a “standard enzyme”, errors in the quantification of the standard enzyme activity would result 
in under- or over estimation of all subsequent sample activities. Such an error may result in 
large scale product losses. Moreover, enzyme activity is not static and can be unfavorably 
affected by many factors ranging from improper storage to agitation during transport. Because 
enzyme activity is only quantified at designated distribution posts, enzyme activity cannot be 
guaranteed upon delivery to the client. Furthermore, prolonged storage, as would be common 
with small dairies, may also result in loss of enzyme activity over time. Since dosage is based 
on a volume per volume basis (ppm) rather than on enzyme activity, accurate activity data is 
essential to ensure appropriate dosage, preventing large scale product losses.  
A sufficiently facile assay, which can be performed on-site, would be advantageous to the 
marketability of the commercial enzyme preparation since dosage may be adjusted more 
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accurately based on enzyme activity. To date no such activity assay is available. However, as 
described in Section 3.2.2, synthetic substrates have been used to determine lipase activity. 
Among these, nitrophenyl based substrates are the most attractive candidates, based on the 
ease of use and versatility. Although pNPB have been shown to act as a substrate for the GCAT 
enzyme, it remains unclear if this substrate can be used for the accurate and sensitive 
quantification of enzyme activity.  
In order to evaluate if pNPB may be used for activity quantification, the kinetics of GCAT 
catalysis, using pNPB as substrate, must be compared to kinetics obtained using the natural 
substrate, lecithin. Since the rate of enzyme catalysis often varies significantly when using 
different substrates, the definition of a single unit of enzyme activity would not necessarily be 
the same for both substrates. The definition of a unit of enzyme activity should therefore be 
defined by comparison to activity data obtained from assays using lecithin as substrate. 
However, although seemingly straight-forward, a kinetic study of GCAT has never been 
described. This is mainly due to the complex nature of phospholipid substrates in buffered 
systems. 
3.3.2 The current model of the GCAT reaction 
In earlier reports of phospholipid hydrolysis by GCAT, Hilton and Buckley82 described a two-step 
interaction of the enzyme with phospholipid substrates as depicted in Figure 3.1. In this 
mechanism GCAT first binds the phospholipid polar head groups, followed by membrane 
penetration and formation of the enzyme substrate complex. This mechanism is similar to 
interfacial lipid hydrolysis by lipases133. 
During its reaction with water-insoluble substrates, such as phospholipids, GCAT, like lipases, 
act at water-lipid interfaces40,82,96. Studies have shown that the overall catalytic rate of lipases 
are regulated by the physicochemical character and organizational dynamics of the 
interface133,134. Reactions catalyzed by GCAT, and other lipases, are therefore two-dimensional 
in character since phospholipid/interfacial binding precedes formation of the enzyme substrate 
complex as presented in Figure 3.1. In many cases, interfacial binding have been shown to be 
rate limiting133. In contrast, Hilton and Buckley82 indicated that binding of the polar head groups 
may not be essential to GCAT catalysis. 
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Figure 3.1 Illustration of the two-step interfacial reaction mechanism of GCAT as proposed by Hilton and Buckley
82
. 
In this representation, formation of the enzyme-substrate complex is preceded by enzyme binding to the polar head 
groups of phospholipids. 
More recently, Hilton et al.39 suggested that GCAT does not require the interfacial activation 
which characterizes lipases. The mechanism whereby GCAT catalyzes interfacial phospholipid 
hydrolysis is therefore still not fully understood. However, Buckley76 suggested that hydrogen 
bonding between the hydroxyl group of the acyl acceptor and the ester linkage of the donor may 
play an important role in the active site of the enzyme. Since cholesterol is incorporated into 
membranes so that the hydroxyl group of cholesterol is in alignment with the ester bond of 
phospholipid, this scenario appears feasible. 
Since, to the best of our knowledge, no kinetic data exists for either of the reactions catalyzed 
by GCAT, there is no kinetic data to support either of the possibilities described. It therefore 
remains possible that rapid equilibrium is reached, and GCAT catalysis occurs via a Michaelis-
Menten kinetic model. In order to explore this possibility, kinetic assays are required. 
3.4 SUBSTRATES FOR GCAT KINETIC ANALYSIS 
3.4.1 Small unilamellar vesicles as enzyme substrates 
Due to the hydrophobic nature of the substrates, GCAT activity assays have often relied on the 
preparation of the experimental lipid vesicle substrates; liposomes, as depicted in Figure 3.2135. 
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Upon hydration of dried lipid cakes, phospholipid membranes spontaneously form due to the 
unfavorable interaction between hydrophobic phospholipids and water136. The hydrated lipid 
cakes subsequently become fluid and swell. Agitation of the swollen lipid cakes results in the 
formation of energetically favorable multilammelar vesicles (MLVs). Once formed, the size of 
MLVs can be reduced by applying energy in the form of mechanical mixing (extrusion) or 
sonication135–137. Sonication of MLV suspensions results in the formation of small unilamellar 
vesicles with an average size of 250Å136.  
MLVs are often too large or heterogeneous for use in enzyme activity studies. SUVs are 
therefore among the most widely used experimental phospholipid membranes39,77,78,136. The use 
of SUV‟s as experimental substrates for GCAT activity assays have been described in 
combination with radiolabeled lipids and/or sterols56,76,78,82,84,138. However, although the use of 
radiolabeled substrates increases sensitivity and eliminates the need for extraction controls and 
internal standards, for large scale industrial application radioactive waste production is a major 
concern. The preparation of SUVs is furthermore laborious and time consuming. 
 
Figure 3.2. General depiction of vesicle formation starting with dried lipid films. Multilammelar vesicle formation 





SUVs can be prepared by using either a probe or a bath sonicator136. Selection of a specific 
sonication method is dependent on the lipid suspension required. Probe sonication is mostly 
used when high energy in small volumes is required. As the sample volume is increased, 
energy distribution is significantly affected. Uneven energy distribution may reduce the ability to 
form uniformly sized lipid vesicles. Probe sonication is therefore mostly used for high lipid 
concentrations or viscous suspensions with small volumes136. However, due to the small sample 
size and high energy input, there is a significant risk of lipid degradation due to excessive heat 
production and increased gas exchange136. It is therefore essential that sonication temperature 
is regulated at all times. Lipid suspensions may also be contaminated with titanium particles 
released from the probe. These particles must be removed by centrifugation prior to use of the 
vesicles. For these reasons bath sonication is more widely used for the preparation of SUVs. 
Bath sonication enables the preparation of larger volumes of SUVs. Because of the larger 
volumes, ultrasonic irradiation is more homogeneous leading to increased reproducibility136. 
Furthermore, temperature regulation is not as crucial as with probe sonication because the heat 
generated by sonication is easily absorbed by the bath. However, it is important to maintain 
sonication temperature above the transition temperature (Tm) of the lipid with the highest Tm in 
the suspension136,139. The Tm is an indication of when a specific lipid will undergo transition from 
the solid gel state to the fluid state136,140. At temperatures below Tm the packaging of 
phospholipid head groups is weakened and the gel phase fluidity is increased136. Above Tm the 
membranes condense causing a reduction in area, a closer packaging and a decrease in 
fluidity136. Therefore, when temperature regulation is required, as is the case with saturated lipid 
suspensions, the bath temperature may easily be regulated with a thermostated water bath. 
Although bath sonication has several advantages over probe sonication, when larger volumes 
are required, bath sonication would not yield a homogeneous suspension of SUVs136. This is 
due to a larger area of ultrasonic radiation136. If vesicles of uniform size are required, 
chromatography or centrifugation may be used to remove larger liposomes. 
3.4.2 Incorporation of cholesterol into SUVs 
Cholesterol is an important component of biological membranes. Apart from decreasing the 
permeability of the membrane to fluids such as water, cholesterol also plays a role in 
stabilization of the phospholipid bilayers136,141–144. As can be seen from Figure 3.3.A, cholesterol 
contains a planar steroid nucleus composed of four fused rings (A,B,C and D), a β-hydroxyl 
group attached to the 3-carbon of the A ring and an aliphatic side chain136,142,143. Being 
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amphipathic in nature, cholesterol is inserted into lipid bilayers with the hydroxyl group oriented 
toward the aqueous phase and the aliphatic side chain aligned with the fatty acyl chains of 
phospholipids as presented in Figure 3.3.B 136,142. The hydroxyl is in alignment with the ester 
linkages of the phospholipids, while the rigid steroid rings associates with the first few carbons 
of the phospholipid acyl chains145. This association reduces the freedom of movement of the 
phospholipid chains, which improves membrane rigidity and reduces membrane permeability to 
water136,146.  
Cholesterol cannot form bilayer structures in the absence of phospholipids. However, in the 
presence of phospholipids cholesterol is able to incorporate into membranes in high 
concentrations (typically 2:1 molar ratios)136. The distribution of cholesterol in membranes is 
furthermore not random. It has been shown, with space filling models, that membrane 
components are packed in a two-dimensional lattice of linear arrays, with cholesterol rows 
altering rows of phospholipid at equimolar concentrations136,145. Cholesterol concentrations in 
excess of 50 mol % would disrupt the linear arrays of alternating cholesterol and phospholipid, 
decreasing the ability to form intact SUVs136. At concentrations higher than 50 mol %, it was 
shown that phase transition is also eliminated and the enthalpy of phase change is reduced to 
zero, decreasing the fluidity of the membranes, and inhibiting hydrocarbon crystalization136,145.  
  
Figure 3.3. (A) Chemical structure of cholesterol indicating the different sections of the molecule, and (B) the position 
of cholesterol incorporation in lipid membranes (Figure recreated from sources 
142,145
) 
SUVs may therefore be used to monitor both the lipase and transferase activities of GCAT 







concentrations. Vesicles containing cholesterol are well suited for general enzyme activity 
assays. However, quality emulsions are not easily obtained. In order to overcome the difficulties 
associated with preparation of quality emulsions, various novel approaches, such as the use of 
synthetic water soluble substrates and enzyme coupled assays have been described115,132,147. 
One such substrate is pNPB. 
3.4.3 pNPB as substrate for GCAT activity monitoring 
While studying the reaction mechanism of GCAT, Buckley et al.77 showed that the hydrolysis of 
several synthetic nitrophenyl esters are also catalyzed. Among the substrates investigated, it 
was found that the reaction rate was the highest when pNPB was used. It has furthermore been 
shown that this substrate is also an effective donor for enzyme catalyzed acyl transfer to 
cholesterol. The use of nitrophenyl substrates enabled the continuous monitoring of GCAT 
hydrolysis. The reaction of pNPB with GCAT is depicted in Figure 3.4. In this reaction the ester 
bond is hydrolyzed by GCAT yielding butyric acid, or cholesteryl butyrate depending on the 
presence of cholesterol, and 4-nitrophenol (4NP). Under basic conditions, 4NP is deprotonated 
to yield 4-nitrophenolate which has an intense yellow color and a strong absorbance at 400 nm 
(ε400 =12000 M
-1 cm-1)78,148. Substrate production can consequently be continuously monitored 
on a thermostated kinetic spectrophotometer. Since the reaction rate is monitored in real-time, 
activity quantification is more accurate and reproducible than conventional assays using lipid 
substrates. Assays using these substrates are furthermore readily scalable to enable high-
throughput activity monitoring in microtiter plates. 
41 
 
Figure 3.4. Enzymatic hydrolysis of pNPB by GCAT followed by subsequent deprotonation of pNP under basic 




The use of SUVs as substrates for the study of hydrolytic enzymes is well established. 
However, its use for routine enzyme activity monitoring is limited by the difficulty to produce 
quality emulsions and the need for specialized equipment for the detection of reaction 
products133,134. As a result synthetic substrates, whose reaction products can be easily detected, 
are increasingly being used for routine analysis. 
The use of pNPB enables continuous reaction monitoring of both reactions catalyzed by GCAT. 
However, it remains to be shown if pNPB can serve as sole substrate for activity monitoring. 
Comparison of the kinetic parameters obtained from studies using phospholipids and pNPB as 
substrate would indicate if this synthetic substrate can be used for routine activity 
determinations. Since no kinetic data is currently available, such studies may also provide 
evidence for the mechanism whereby GCAT interacts with substrates. This thesis will describe 
the development of assay methods, both continuous and discontinuous, which may be used for 
the kinetic analysis of GCAT catalysis. The data obtained from these studies will then be 




CHAPTER 4  
 
FOODPRO® CLEANLINE APPLICATION TRIALS 
4.1 INTRODUCTION  
From the discussion in Chapter 2 it is clear that fouling is a common phenomenon during ultra-
high temperature (UHT) treatment of dairy products, resulting in an increase in plant downtime 
and input cost. As described in this chapter, DuPont® recently isolated a bacterial enzyme, 
glycerophospholipid cholesterol acyltransferase (GCAT, E.C: 2.3.1.43), which can reduce 
fouling by preventing the aggregation and precipitation of proteins denatured by UHT treatment. 
However, prior to commercial promotion it is essential to validate the efficiency of the 
commercial GCAT preparation, FoodPro® Cleanline (FPCL). For this purpose, accurate 
methods for the quantification of GCAT reaction products are crucial since incorrect 
dosage/usage of FPCL may lead to overproduction of free fatty acids (FFA). An overabundance 
of FFA may reduce the economic value of the final product by increasing product rancidity. In 
this chapter the current method for the quantification of GCAT reaction products was evaluated 
prior to application of FPCL in pilot and factory scale trials. This was important since this method 
was required for quality control purposes subsequent to each trial. This chapter will therefore 
describe the evaluation of this analysis method followed by the application of FPCL in various 
pilot and factory scale UHT trials. 
4.2 MATERIALS AND METHODS 
All FPCL preparations used in this section were from commercial preparations provided by 
DuPont® SSA Dairy innovations center Cape Town, South Africa. Unless specified otherwise 
Mat# A14076G190, Batch# 4861927699 FoodPro® Cleanline (FPCL) was used for all trials. 
4.2.1 UHT product analysis 
The free fatty acid (FFA) and cholesterol/cholesteryl ester content of milk samples, collected 
from pilot- and factory scale FPCL trials, were evaluated by gas chromatography using the 
method recommended by DuPont®, Bruges. In this section, this method will be evaluated. 
Milk samples were prepared for gas chromatographic (GC) analysis by liquid-liquid ether 
extraction. For this purpose one mL milk was accurately measured into a 15 mL teflon-lined 
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screw cap tube containing 2 mL 96% ethanol and 1.5 mL deionized water. The contents were 
thoroughly mixed, followed by the addition of 0.3 mL NH4OH. A phenolphthalein indicator (10 µl 
20% (w/v)) was added to increase visualization of phase separation. This mixture was 
mechanically shaken for 5 min on an IKA Vibrax VXR shaker. After 5 min agitation, 5 mL methyl 
tert-butyl ether (MTBE) was added followed by shaking for 5 min. Petroleum ether (5 mL, 40 – 
60 °C) was added and the mixture was again mechanically shaken for 5 min. The solvent top-
layer was clarified by centrifugation at 3500 x g for 10min. The clear organic phase was 
subsequently transferred to a clean glass test tube and the extraction was repeated as follows: 
The organic phase was again clarified by centrifugation as described above. The solvent phase 
was pooled with the first extract and the solvent was evaporated under a stream of nitrogen at 
60 °C. The resulting lipid extract was prepared for GC analysis as described in the ensuing 
section. 
Following lipid extraction, the extracts were dried under a stream of nitrogen at 60°C. The dried 
lipids were resuspended in a volume (1.5 mL) of heptane: pyridine (2:1) containing an internal 
standard of heptadecane. Aliquots of 500 µL were subsequently transferred to clean crimp cap 
vials and treated with 100 µl N-methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA) containing 
1% trimethylchlorosilane (TMCS). The vials were subsequently sealed and heated at 60°C for 
15 min. Following derivatization, the samples were ready for GC-MS analysis. 
GC-MS analyses of cholesterol and cholesteryl ester derivatives were performed using an 
Agilent 6890N GC (Agilent Technologies Wilmington, USA) coupled to an Agilent 5975 MS 
detector. A Restek (12723-127) 30m x 250 µm (inner diameter) x 0.25 µm (film thickness) Rtx®-
5Sil MS Capillary Column was used for separation. Of each derivatized sample 1µl was injected 
using a CTC PAL autosampler in splitless-injection mode into the injection port, set at 300°C. 
High purity helium (99.999%) was used as the carrier gas at a constant flow of 1.0 mL/min. The 
GC oven temperature program applied was as follows: the initial temperature was set at 150°C, 
and held for 1 min. The oven temperature was then increased to 330 °C at a rate of 10°C/min 
Add 1 mL ethanol  – Mechanically shake for 5 min. 
Add 5 mL MTBE  – Mechanically shake for 5 min. 
Add 5 mL petroleum ether  – Mechanically shake for 5 min. 
and maintained at 330°C for 10 min. Full scan (m/Z 35 – 700) and single ion monitoring (SIM) 
was used for detection. SIM was used to identify trimethylsilyl palmitate (m/Z 313), trimethylsilyl 
stearate (m/Z 341), cholesta-3,5–diene (
m/Z 368), cholesta-4,6–diene (
m/Z 368) and trimethylsilyl 
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4.2.2 UHT trials 
4.2.2.1 Pilot scale trials 
Unless stated otherwise, all pilot scale trials were performed at DuPont® Nutrition and Health 
Cape Town (South Africa) using an OMVE HT220 HTST/UHT continuous flow processing 
system under the supervision of senior application specialist, Peter Lawson. Fresh pasteurized 
full cream milk was used for these trials. Prior to the addition of FPCL, the milk was subjected to 
various tests to ensure milk quality. These tests included analysis of the physical milk 
properties, i.e. % fat, % protein, % lactose and pH using a Milkoscan™ analyzer followed by an 
alcohol test with 75% ethanol. A volume of milk was subsequently spiked with 10 ppm FPCL 
and incubated at ≤ 5°C for at least 2 hours prior to UHT processing. Unspiked milk was 
processed in the same manner as a control. 
Two successive full clean in position (CIP) and sterilization cycles were performed prior to UHT 
processing. The tubular heating and pre-heating sections were opened and the tubes and static 
mixers were visually inspected prior to processing. UHT processing was performed at 20 liter 
per hour, using tubular heat exchangers, at 142°C with 4 seconds holding time followed by 
cooling to <25°C for aseptic filling. The homogenizer pressure was set at 200 bar (first 
stage/second stage, 150/50) at 65°C and temperature (∆T) and pressure differentials were 
noted every 30 min. Samples of 250 mL were collected for analysis 10 min after the arrival of 
product at the sampling valve. Samples were collected in heat-sealed UV-resistant plastic 
bottles and stored at 4°C until analysis. Following UHT processing, the heat exchangers were 
visually inspected for fouling prior to CIP. 
4.2.2.2 Full scale factory trials 
Factory trials were performed at Dewfresh in Leandra, South Africa under the supervision of the 
Director, Mr Stefan Swanepoel. For these trials fresh milk, previously standardized and clarified, 
was spiked with 10 ppm FPCL and incubated for 2 hours at 4°C with agitation. Thermal 
processing was performed at  6000 L per hour using a tubular UHT system (Finnah, Finnahmat 
6500/065). Milk temperature was increased to 142°C and held for 6 seconds with the 
homogenizer pressure set at 200 bar (first stage/second stage, 150/50 at 65°C). The milk was 
cholesterol (M/Z 458). The MS source temperature was set at 230°C and the MS quadrupole 
temperature at 150°C. 
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subsequently cooled to 20°C for aseptic packaging. ∆T values were noted every 30 min and 1 l 
samples were collected from the packaging line at random intervals for analysis.  
4.3 RESULTS AND DISCUSSION 
Unless specified otherwise all experiments were performed at least in duplicate, and the data 
presented as the mathematical mean.  
4.3.1 GC-MS analysis 
In order to ensure optimal product quality, a method for the quantification of GCAT reaction 
products (cholesterol, cholesteryl ester and FFA) is critical. The method currently used by 
DuPont® for evaluation of product quality is GC coupled to flame ionization detection (FID). 
Although this method is sufficiently sensitive for the low level detection of cholesterol, 
cholesteryl esters and FFA, it does not allow for peak identification without prior injection of a 
pure standard. Even when the retention time of a specific compound is known, peak overlapping 
may result in a decrease in detection sensitivity. In order to overcome this drawback, GC-mass 
spectrometry (GC-MS) may be used. This analysis technique allows for the identification of 
individual compounds based on their specific mass to charge ratio (m/Z) following ionization. 
Furthermore, the M/Z values obtained can be compared to a library for peak identification without 
prior injection of a pure standard. 
For the GC analysis of cholesterol and FFA, derivatization is required to improve gas 
chromatographic behavior and detectability by increasing volatility and/or stability of the 
compounds of interest. During derivatization reactive functional groups are silyated by MSTFA 
yielding trimethylsilyl derivatives of the compounds of interest. Reactive functional groups (such 
as an HO-R) are thus essential for derivatization. Figure 4.1 illustrates the general reaction 
mechanism for derivatization of an alcohol functional group by MSTFA and TCMS (99:1). 
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Figure 4.1 General reaction mechanism for silyation of an alcohol functional group using MSTFA and 1% TMCS as 
derivatizing reagents where R = cholesterol. 
In this derivatization TMCS is the main silyl donor. However, TMCS only constitutes 1% of the 
derivatization reagent used. During derivatization TMCS acts as a catalyst that promotes TMCS 
formation via MSTFA cleavage. This method of TMCS cycling is used to prevent the excessive 
formation of HCl which would occur if TMCS is used as sole derivatizing reagent. 
The chemical structures of cholesterol (a), cholesteryl stearate (b), cholesteryl palmitate (c) and 
heptadecane (d) are depicted in Figure 4.2. From these figures it can be seen that only 
cholesterol has a functional group that can be derivatized by silyation. As a result, derivatization 




Figure 4.2 Chemical structures of (A) cholesterol, (B) cholesteryl stearate, (C) cholesteryl palmitate, (D) 
heptadecane, (E) cholesta 3,5 diene, (F) cholesta 4,6 diene and (G) cholesterol trimethylsilyl ether
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. 
From Figure 4.3, however, it can be seen that multiple peaks are observed when pure 
cholesteryl ester standards were injected. Comparing the m/Z values obtained for each peak to a 
library, it was found that the peaks at 9.18 and 10.92 min correspond to silyated FFAs 
corresponding to the acyl chain from each injected cholesteryl ester standard. The remaining 
peaks correspond to the cholesteryl ester breakdown products, cholesta-3,5–diene, cholesta -
4,6–diene and cholesterol trimethylsilyl ether at 15.23, 16.04 and 17.62 min respectively as 
depicted in Figure 4.2 (E-F). 
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Figure 4.3 Chromatograms obtained after 1µl injection of 200 ng pure standards of cholesteryl palmitate (solid line) 
and cholesteryl stearate (dashed line) analyzed with GC-MS as described in the text. 
To determine if cholesteryl esters were hydrolyzed during derivatization or ionization, MS and 
FID detection methods were compared. From Figure 4.4 it can be seen that multiple peaks are 
produced irrespective of detection method. These results suggest that cholesteryl ester 
breakdown occurs during derivatization rather than during ionization. Consistent with this, 
Onorato et al.151 suggested that derivatization for GC-MS is complicated by isomerization and 
decomposition of lipid side chains during ester analysis152.  
 
Figure 4.4 GC-FID chromatogram of 1µl injection of 200 ng pure standards of cholesteryl palmitate (solid line) and 
cholesteryl stearate (dashed line) with internal standard (IS) and cholesteryl ester breakdown products (CEBP). 
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GC analysis of a mixture consisting of cholesterol and cholesteryl esters would consequently 
result in an overestimation of the cholesterol content and an underestimation of the cholesteryl 
ester content. Furthermore, since FFAs are also a product of cholesteryl ester derivatization, 
this method is also not suitable for the quantification of FFAs in treated milk samples. Other 
methods for the quantification of cholesterol, cholesteryl esters and FFAs are therefore essential 
for accurate evaluation of GCAT reaction products.  
4.3.2 UHT trials 
The general process-flow of all trials performed is depicted in Figure 4.5. For pilot scale trials 
previously pasteurized commercial milk was used. In all trials performed milk was incubated for 
at least two hours at ≤ 5°C prior to UHT processing. 
UHT Milk factory process-flow  
 
Figure 4.5 General UHT milk process-flow used during all trials. 
Fouling cannot be observed directly during thermal processing. However, various operational 
parameters may be used in order to monitor fouling153. During these studies two detection 
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methods were used since these methods can be used universally. The first parameter used was 
∆T. Deposit formation reduces the heat transfer capacity of the heat exchangers. The 
temperature of the heating medium must therefore be increased in order to maintain a constant 
product temperature of 142°C. The difference in temperature between the heating medium and 
product, referred to as ∆T, can therefore be used to monitor fouling. Fouling related increases in 
∆T typically results in a fouling profile wherein ∆T remains fairly constant for the first few hours 
of processing followed by a rapid increase in the last hours of processing. This profile is due to a 
series of events that take place at the solid-liquid interface. As discussed in Chapter 2, mineral 
fouling is the predominant form of fouling during UHT processing. However, protein fouling 
precedes mineral fouling resulting in a “lag phase” wherein protein adsorption to the solid heat 
exchange surface takes place4. Once formed, the homogeneous proteinaceous layer acts as a 
scaffold for mineral deposition leading to mineral fouling. In order to ensure efficient operation of 
the UHT plant, it is advised to keep ∆T below 5°C. Once this value is reached, processing 
should be ceased and the heat exchangers cleaned by an intermediate rinse or full CIP. 
In addition to temperature differentials, system back pressure may also be used to monitor 
fouling. Thermal processing is performed at temperatures above the normal boiling point of 
water at atmospheric pressure. To prevent flash boiling of the product in the holding tubes 
and/or heat exchangers, processing is performed at increased pressure. Product flashing may 
result in product burn-on and, consequently, off flavours. Deposit formation increases the 
system back pressure by obstructing the flow path of the product. In order to maintain a 
constant back pressure, pressure regulation valves are automatically adjusted in response to 
variations in back pressure. However, this regulation is limited. Once back pressure buildup 
exceeds the maximum capacity of the pressure regulation valve, system back pressure will 
increase rapidly due to a lack in regulation. In order to prevent damage to the holding tubes, 
UHT processing must be stopped and the processing plant cleaned.  
4.3.2.1 Pilot scale trials 
Full scale UHT plants operate at processing flow rates in excess of 5000 L product per hour. 
Due to these high volumes along with the high running costs, full scale trials are not financially 
viable for research and development (R&D) purposes. For R&D, pilot scale UHT plants are 
more suitable due to ease of operation, lower flow rates (up to 150 L per hour), and support for 
multiple heat exchangers. Using pilot scale plants, product development can be performed 
leaving full scale commercial UHT processing unhindered. For this reason, pilot plant trials were 
51 
conducted in order to evaluate the effect of FPCL on plant fouling and final product quality prior 
to factory application. During these trials ∆T and back pressure was used to monitor fouling.  
Throughout 2012 various pilot scale trials were conducted to evaluate the effect of FPCL on 
UHT plant fouling and the final product quality. Initially, however, no significant difference could 
be demonstrated between enzymated and non-enzymated milk. Similar results were obtained 
for subsequent pilot scale trials performed (two additional trials). Upon investigation it was found 
that the FPCL used (Mat# A14076G190 Batch# 1781369165) had less than 25% of the 
expected activity. Failure to demonstrate a significant difference, between treated and untreated 
milk on UHT plant fouling, was subsequently attributed to a lack in enzyme activity.  
The trial was subsequently repeated with fresh FPCL with a validated enzyme activity. When 
comparing the operational parameters (∆T and back pressure) from these trials a number of 
differences were observed. As can be seen in Figure 4.6, there was a substantial difference in 
∆T values. UHT processing performed without the addition of FPCL (control) resulted in a 
typical fouling profile wherein ∆T remained fairly constant for the first 2 hours of processing 
followed by a rapid increase in the last hour of processing. The maximum recommended ∆T 
was exceeded after 2.5 hours, and the trial was terminated to prevent damage to the holding 
tubes and static mixers. In contrast, the ∆T of milk spiked with FPCL (enzymated 1 and 2) did 
not increase substantially, even after 3.5 hours of processing. 
 
Figure 4.6 ∆T fouling profiles of UHT processing performed on milk samples with and without FPCL. In this figure 
Enzymated 1 and 2 represents duplicate trials performed using FPCL. 
From Figure 4.7 is can be seen that enzymation also resulted in a reduced rate of back 
pressure buildup. The system back pressure for the control trial was below that of trial 2 for the 
52 
first 2 hours of processing. However, a rapid pressure increase of 4 bar (ca. 85%) was observed 
30 min prior to termination of the trial. In contrast, system back pressure remained constant for 
at least 60 min prior to the end of trials performed with enzymated milk. Compared to the 
control, the system pressure for enzymated trials 1 and 2 increased by 33% and 66% 
respectively. Although a substantial increase in operational back pressure was observed for the 
second enzymated trial, this increase was substantially less (44%) than that of the control trial. 
The back pressure of the trials with FPCL was furthermore stable prior to termination of the 
experiment while the pressure of the control trial increased at a constant rate. 
 
Figure 4.7 Graph indicating an increase in system backpressure as a result of deposit formation during UHT plant 
fouling. 
Following thermal processing the static mixers were opened and visually examined. Figure 4.8 
shows the visual inspection of the static mixers of trials without (A) and with FPCL (B). Although 
a layer of fouling deposit was observed in both trials, this was substantially less on the product 
side mixer (encircled in red) for the trial with FPCL, even after an additional hour of processing. 
Furthermore, the overall fouling layer of the control trial was more brown in colour indicating 
caramelization. Caramelization, and burn-on, imparts a burnt taste on the products, reducing the 
product appeal154. Excessive burn-on may also lead to a increased cleaning time and damage 
to the heat exchangers. It is therefore recommended to avoid burn-on at all costs. 
The results obtained from the pilot plant trials indicated that the use of FPCL could increase 
thermal processing time by up to 30%. Although the data for a single trial was discussed, the 
results were highly reproducible after obtaining fresh FPCL. The results also suggest that 
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caramelization and burn-on may be reduced with the use of FPCL, resulting in an increased 
product appeal.  
 
 
Figure 4.8 Static mixers of the OMVE HT220 HTST/UHT pilot scale thermal processing plant subsequent to thermal 
treatment of fresh pasteurized full cream milk (A) with FPCL and (B) without FPCL. 
4.3.2.2 Full scale factory trials 
Based on the success of the pilot scale trials, full scale factory trials were performed as 
described in Section 4.2.2.2. In these trials fouling was monitored by system back pressure. 
Unfortunately no previous ∆T data was available as control because, under normal operation, 




data for control processing runs as well as runs with enzymated milk. The UHT processing plant 
used has a maximal pressure limit of 21 bar. Once this pressure was reached, processing is 
terminated in order to prevent damage to the heat exchangers during processing. 
During normal production, low fat milk is processed prior to full cream milk in attempt to reduce 
fouling. In order to enable the use of previous processing data as a reference, the FPCL trial 
was performed similarly. An equal volume (25000 L) of low fat milk, also containing FPCL, was 
therefore processed prior to full cream milk. From each batch, two samples were collected at 
the beginning and the end of production. Samples were collected ca. 10 min apart.  
From the results presented in Figure 4.9 it can be seen that, although no control data is 
available, ∆T remained constant throughout the trial. The maximal ∆T value obtained during this 
trial was 0.8°C. This was significantly lower than the 5°C ∆T limit, indicated as the red line, even 
after prolonged processing. 
 
Figure 4.9 ∆T values obtained from full scale UHT production with the addition of FPCL In this figure the red line 
indicates the maximum back pressure limit. 
The pressure data obtained from the full scale factory trials, conducted at Dewfresh, is depicted 
in Figure 4.10 . Upon comparison with the data obtained from pilot scale studies (Figure 4.7) a 
similar back pressure profile was observed for the control trial without FPCL. During these trials, 
as with pilot scale trials, system back pressure remained constant for the first hour of 
processing. This was followed by a gradual increase in back pressure and a rapid spike 30 min 
prior to termination of UHT processing. In comparison, addition of 10 ppm FPCL resulted in a 
more gradual increase in back pressure and an elimination of the pressure spike.  
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Under normal processing conditions, without the addition of FPCL, an intermediate wash was 
required after 4.5h of processing ( 26500 L milk). With the addition of 10 ppm FPCL the 
processing time was increased to 8.5 h. However, the venue for the trial was a medium scale 
production facility and has a maximal production capacity of 50000 L milk per day. At a 
processing rate of 6000 L per hour this limit was reached after 8.5 h. The results presented 
suggest that the 8.5 h could be improved on even further if larger storage tanks were available. 
Repeating the trials described at a larger venue will therefore be an interesting avenue to 
persue. 
 
Figure 4.10 Back pressure profile of full scale UHT trials. 
The studies conducted in this section illustrate the benefit of FPCL on UHT processing 
efficiency. However, the increase in efficiency was only achieved when the enzyme activity was 
within the specified range. Because FPCL is dosed on a volume per volume basis (ppm) rather 
than on enzyme activity the results obtained in the first pilot scale trials illustrate the need for 
enzyme activity confirmation prior to dosage. Currently the enzyme activity of FPCL is 
exclusively determined at designated distribution posts of which there are none in Sub-Saharan 
Africa. The commercial FPCL preparation is therefore distributed as having between 900 and 
1100 units of enzyme activity (Addendum A). Since enzyme activity is not static, and may be 
affected by various factors including incorrect handling and storage, the results obtained 
illustrate the need for a facile and accurate method for enzyme activity verification prior to use. 
To date, no such assay has been described. 
Availability of an FPCL activity assay, which is sufficiently simplistic and accurate, would 
increase the commercial value of FPCL by instilling confidence in the product quality. Such an 
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assay could also be used in determining the applicability of FPCL in different processing 
methods such as the Scania method used for the production of 2% milk and 40% cream. 
4.4 CONCLUSION 
The data presented in this chapter clearly indicates the benefit of FPCL during UHT processing 
of milk. These benefits include an increase of up to 100% in the total uninterrupted thermal 
processing duration. The results presented suggest that the use of FPCL will consequently 
result in an increase in the commercial profit margin of UHT milk. However, for successful 
application accurate methods for the monitoring of GCAT reaction products are needed. In this 
study product analysis by GC analysis, using the proposed method, resulted in hydrolysis of 
cholesteryl esters during sample preparation. A different method of product analysis is therefore 
required. Various enzyme linked kits are commercially available for this purpose, however, its 
use in milk analysis first needs to be evaluated. 
The results obtained from pilot scale studies furthermore indicated a need for a facile method for 
GCAT activity verification in FPCL. Accurate activity data is essential to the successful 
application of GCAT in a commercial setting. This was especially evident from the initial pilot 
scale trials wherein no substantial effect could be shown after addition of FPCL. Availability of a 
rapid and accurate assay would not only increase the marketability of FPCL, but may also be 
used in the evaluation of applicability to different processing methods. 
Based on the findings shown in this chapter, the following chapters will describe investigations 
of various methods which may be used for the quantification of GCAT reaction products in milk. 
These methods will subsequently be used for the development in an accurate reproducible 
activity assay for GCAT activity monitoring. Finally, the methods described will be used for the 
analysis of milk samples obtained from the pilot- and factory scale trials described in this 
chapter. 
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CHAPTER 5  
EVALUATION OF METHODS FOR THE QUANTIFICATION OF GCAT 
REACTION PRODUCTS AND THE PARTIAL KINETIC 
CHARACTERIZATION OF GCAT 
5.1 INTRODUCTION  
The mechanism of action and molecular characteristics of GCAT have been the topic of 
extensive research. The lack of co-factor requirement and stability under diverse reaction 
conditions makes GCAT an attractive candidate for application in industries such as dairy. 
However, for successful industrial application, various quality control procedures must exist 
whereby enzyme reaction products can be quantified. In Chapter 3 it was shown that the current 
method for quantification of cholesteryl esters and free fatty acids (FFA) results in the hydrolysis 
of cholesteryl esters yielding cholesterol and FFAs as products. The need for an accurate, 
facile, activity assay was furthermore illustrated in this chapter. The difficulties discussed could 
result in large financial losses due to product quality deficiencies. In the case of GCAT, incorrect 
dosage and/or incubation times may lead to excessive FFA production which could render an 
entire batch of milk unusable. Accurate methods for the quantification of FFA, cholesterol, 
cholesterol esters and enzyme activity are therefore vital. This chapter describes the evaluation 
of chromatographic and enzymatic methods for the quantification of cholesterol, cholesteryl 
esters and FFA. These methods were subsequently used for FPCL quality control analysis and 
the development of an activity assay for the partial kinetic characterization of GCAT. 
5.2 MATERIALS AND METHODS 
Unless specified otherwise, all reagents and solvents used were of analytical grade and 
purchased from reputable scientific suppliers. Cholesterol/cholesteryl ester quantitation kit was 
obtained from Abcam® (Cambridge, United Kingdom). The NEFA free fatty acid (FFA) 
quantification kit was acquired from WAKO Chemicals (Neuss, Germany). Pierce BCA protein 
quantification kit was acquired from Pierce chemical company (Rockford Ill, USA). 
 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), Fluka para-Nitrophenyl butyrate (pNPB), 
 4-nitrophenol (NP) and cholesterol was obtained from Sigma-Aldrich (St Louis MO, USA). 
26(27) - 14C cholesterol (53 mCi/mmol) was purchased from Amersham International (United 
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Kingdom). Kieselgel 60-F254 thin layer plates were from Merck (Darmstadt, Germany). All 
solvents used for normal phase high performance liquid chromatography (HPLC) and thin layer 
chromatography (TLC) were dried using 4Å molecular sieve (Merck Darmstadt, Germany) and 
filtered through 0.45 µm HVHP filter paper (Millipore) prior to use. Greiner bio-one 96 well flat 
bottom microtiter plates were purchased from Greiner (Frickenhausen, Germany) 
Unless stated otherwise, all enzyme solutions used were obtained from DuPont® SSA Dairy 
Innovation Center Cape Town, South Africa. The enzyme solutions used were from commercial 
stocks and were stored as per manufacturer instructions. Unless specified otherwise Mat# 
A14076G190, Batch# 4861927699 FoodPro® Cleanline (FPCL) was used for all assays. Protein 
content was determined using the Pierce bicinchoninic acid (BCA) protein determination kit with 
bovine serum albumin as standard. Food grade deoiled soy lecithin (Solec™ F), used for activity 
studies, was obtained from Solae™. 
5.2.1 Lipid extraction 
Prior to sample extraction and quantification of GCAT reaction products, lipid extraction 
methods were evaluated in order to ensure maximal extraction efficiency. Percentage recovery 
was calculated by spiking full cream milk with 14C labeled cholesterol (80 000 counts per 
minute). Each extract was resuspended in 100 µl chloroform and the radioactivity was counted 
in a liquid scintillation counter. The following extraction methods were evaluated. 
Method 1 – Hexane extraction with saponification 
One mL milk was accurately measured and added to a 15 mL teflon-lined screw cap tube 
containing 1 mL 10% (w/v) ethanolic KOH. The mixture was subsequently incubated for 30 min 
at 70 °C. The unsaponifiable supernatant was then extracted with 5 mL hexane and 2 mL 
deionized water. The extraction mixture was mechanically shaken for 5 min using an IKA Vibrax 
VXR shaker. After 5 min agitation, the organic upper phase was quantitatively transferred to a 
clean glass test tube. Hexane extraction was repeated three times. 
The resulting extract was evaporated to dryness at 60 °C under a stream of nitrogen using a 
Techne sample concentrator. The extracted lipids were suspended in 100% hexane and directly 
subjected to HPLC analysis.  
Method 2 – Hexane extraction Method 1 but without saponification. 
Method 3 – Ether extraction as described in Chapter 4 Section 4.2.1 but without derivatization. 
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5.2.2 Chromatographic analysis 
All HPLC solvents and sterol standards were purchased from Sigma-Aldrich (Darmstadt, 
Germany). All solvents were HPLC grade, and were filtered prior to use through a Millipore  
0.45 µM pore size type HVHP filter. A Finnigan Surveyor (Thermo Scientific) running 
ChromQuest (version 4.2.34) software was used for all HPLC analysis. Fresh skim milk, used 
as matrix, was obtained from a local supermarket. 
Preparation of sample and standard solutions 
Milk fat was extracted using Method 3 described in Section 4.2.1. The dried extracts were 
dissolved in 100% ethanol by sonication followed by centrifugal filtration, using a Millipore type 
HVHP 0.45 µm pore size centrifugal filter, at 3500 x g for 10 min in a Hermle Z400 centrifuge. 
Lipid extracts were quantitatively transferred to clean 1.5 mL crimp cap HPLC vials (National 
Scientific) and subjected to HPLC analysis. 
A standard solution, containing 1 mg/mL cholesterol, cholesteryl palmitate and cholesteryl 
stearate was prepared by dilution of 20 mg/mL stock solutions with 100% ethanol. A series of 
standards with concentrations ranging from 0 to 0.250 mg/mL was prepared by serial dilution in 
fat free milk prior to lipid extraction. All standards were prepared in duplicate. Of each 
sample/standard 20 µl was injected onto the HPLC column using a Finnigan Surveyor 
Autosampler plus fitted with a 25 µl sample loop. In order to minimize cross contamination 
resulting from multiple injections, the standards were run subsequent to the extracted milk 
samples. Prior to injection of the standards a solvent blank was injected in duplicate. 
5.2.2.1 Reverse phase HPLC methods 
Various solvents were tested as mobile phase for isocratic separation of cholesterol and 
cholesteryl esters. For sterol analysis the following C18 columns were compared: Waters 
Symmetry (4.6 x 150 mm), Waters Atlantis (3.9 x 150 mm) and a Phenominex Luna (4.6 x 150 
mm). After changing the mobile phase, the column was equilibrated with at least 10 column 
volumes, or until a stable baseline was obtained.  
Prior to injection of spiked milk extracts, standard solutions, containing 200 µg of each sterol 
standard, were injected to determine the retention times for each standard. The retention times 
obtained were subsequently stored in a method library to enable the integration of each peak 
after completion of the run. The column temperature was maintained at 30°C in order to 
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compensate for variations in ambient temperature. The general HPLC method used was similar 
with each solvent system and is described in Table 5.1. 
Table 5.1 General method used for isocratic HPLC analysis of milk extracts. 
Flow rate:                                  1.5 mL/min 
Injection volume:                      20 µl 
Detection wavelength:           210 nm 
Spectral scan range:               400 – 190 nm 
Column oven temperature       30 °C 
After a satisfactory solvent system was identified, the separation profiles of different C18 
columns were compared. Each column was thoroughly equilibrated prior to standard injection as 
described previously. Columns were compared based on the retention times, peak areas and 
peak resolution of injected standards. 
5.2.2.2 Normal phase thin layer chromatography method 
Solvent systems consisting of hexane and isopropanol or ethyl acetate were compared with 
TLC using silica backed Kieselgel 60-F254 plates. The retention of individual and mixed 
standards was compared with varying ratios of solvent. TLC plates were developed by spraying 
with 50% sulfuric acid followed by heating at 100 °C for 10 min. For kinetic studies of GCAT a 
mobile phase consisting of 95:5 hexane: ethyl acetate was used. 
5.2.3 Cholesterol quantification using modified Lieberman-Burchard reagent  
Based on an assay described by Kim and Goldberg155, the cholesterol content of aqueous 
samples were quantified following solvent extraction using a modified Lieberman-Burchard (LB) 
reagent. Solvent extracted lipids were resuspended in 100 µL hexane prior to analysis. To 
prepare LB reagent, 40 mL glacial acetic acid was added to 44 mL ice-cold acetic anhydride. To 
this mixture 6 mL ice-cold concentrated sulfuric acid was added. The final concentrations of 
reagents were therefore 40:44:6 glacial acetic acid, acetic anhydride and sulfuric acid. 
The LB assay described in the text was adapted to a microtiter plate based assay with a final 
volume of 200 µL per assay. All incubations were performed at 37°C. The optimal absorbance 
wavelength of LB reagent was subsequently determined. This was achieved performing an UV 
spectral scan (800-480 nm) of a 1 mg/mL cholesterol standard in hexane on a Biotek 
Powerwave 340 microtiter plate reader in Greiner bio-one flat bottom microtiter plates. The 
optimal incubation time was determined by reading the absorbance of 1 mg/mL standard in LB 
reagent in five minute increments at the wavelength determined above for 40 min. The effect of 
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assay volume on incubation time was evaluated by increasing the assay volume to 1 mL. 
Sample absorbance was measured every 30 seconds in a Beckman DU-65 recording 
spectrophotometer at 37°C for a total of 60 min. Variations in the ratio of sample to LB reagent 
were investigated by increasing the volume of standard in relation to LB reagent. The results 
were evaluated by comparison of the absorbance values (minimum and maximum) of a 
standard range of cholesterol standards ranging from 0 – 1 mg/mL. The ratios assayed were 
10:190, 20:180 and 40:160 (µl/ µl) standard: LB reagent. 
5.2.4 Enzyme coupled GCAT product quantification assays  
5.2.4.1 Free fatty acid quantification 
Free fatty acids were quantified using the NEFA HR(2) FFA quantification kit with oleic acid as 
standard. The kit was adapted for use in a microtiter plate assay. The efficiency of this 
adaptation was evaluated as the regression fit of an oleic acid standard dilution series. All 
incubations were performed at 37°C. 
Assay procedure: 
To 20 µL standard/sample, 110 µL reagent R1 was added followed by 5 min incubation at 37°C. 
The absorbance of the reagent blank was subsequently determined at 540 nm in a Multiscan 
EX (Labsystems) microtiter plate reader. After reading the absorbance of the reagent blank, 
55 µl reagent R2 was added to each well and incubated at 37°C for an additional 5 min. 
Following the final incubation the absorbance of each well was determined at 540 nm. The final 
absorbance was calculated by subtracting the first reading from the second. The final 
absorbance and concentrations of the standards were subsequently plotted to produce a linear 
calibration curve. The concentration of FFA in each sample was calculated using this calibration 
curve. 
5.2.4.2 Cholesterol/Cholesteryl ester quantitation 
Total cholesterol and cholesteryl esters were quantified using an enzyme based quantitation kit 
provided by Abcam Biochem. For quantification of cholesterol/cholesteryl esters in milk, milk 
samples were homogenized by Ultra Turrax and diluted 10-fold with distilled water (dH2O) prior 
to each assay. Assays were performed with a 35 µl diluted milk sample as per manufacturer 
instructions. All incubations were performed at 37°C. The fluorescence values were determined 
on a Thermo Varioskan multiplate reader with using an excitation wavelength of 535 and an 
emission wavelength of 590. 
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Enzyme-based cholesterol and cholesteryl esters quantification relies on the use of three 
enzymes namely cholesterol esterase, cholesterol oxidase and horseradish peroxidase (HRP). 
Figure 5.0 depicts the assay principle. In the first reaction, cholesteryl esters are hydrolyzed to 
cholesterol and FFA by the action of cholesterol esterase. Cholesterol is subsequently oxidized, 
by cholesterol oxidase, to cholest-4-ene-3-one and H2O2. The non-fluorescent probe, ADHP, is 
subsequently oxidized by HRP, with H2O2 acting as the electron source, to yield highly 
fluorescent resorufin (Ex/Em = 535/590)156,157. Free cholesterol content can be quantified by 
omission of cholesterol esterase in the first reaction. Cholesteryl ester content is subsequently 
calculated as the difference between total cholesterol (with cholesterol esterase added) and free 
cholesterol. 
 
Figure 5.0 General reaction principle for the enzyme-based quantification of total and free cholesterol
156
 
5.3 ENZYME ACTIVITY ASSAYS 
Prior to all kinetic analysis of FPCL, the protein content of the stock solution was quantified 
using the Pierce BCA protein determination kit with bovine serum albumin as standard. Each 
protein determination was performed in triplicate as per the manufacturer instructions. The 
commercial FPCL preparation contains multiple components. Enzyme spike concentrations 
were subsequently quantified as amount protein, in µg, instead of the mass of the FPCL used. 
5.3.1 Phospholipase activity assay  
5.3.1.1 Substrates for phospholipase activity quantification 
Food grade lecithin was used as substrate for assay development purposes. Prior to all assays, 
the lecithin powder was “washed” with acetone in order to remove residual FFAs and other 
contaminants. This was achieved by suspending 50 g dry lecithin powder in 500 mL acetone 
with stirring for 20 min. The acetone was subsequently removed by vacuum filtration through 
Whatman no. 1 filter paper on a Buchner funnel. The FFA content of a dried powder sample 
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was determined, and washing was repeated until no residual FFA was present. Typically, two 
wash steps were sufficient. 
For kinetic analysis of the hydrolytic activity of GCAT, SUVs, consisting of egg yolk lecithin, 
were prepared as described by Rautenbach158. A dilution series of lecithin, between  
0.05 – 2 mM, was prepared from a 20 mg/mL stock solution in chloroform, in chemically clean 
thin-walled glass test tubes. The chloroform was evaporated under a stream of nitrogen to leave 
a thin lipid film on the glass. The lipid was subsequently resuspended in a 20 mM Tris-HCl, pH 
7.0, buffer containing 160 mM KCl flushed with N2. This suspension was sonicated in a sonic 
bath filled with a 1% Triton X-100 solution until the suspension was translucent. Optimal 
sonication time was initially determined by sonicating a lipid suspension for various time periods 
and visually comparing the translucency and FFA content of the resulting suspensions with 
each other. 
5.3.1.2 Enzyme inactivation studies 
In order to prevent phospholipid hydrolysis following aliquot collection, enzyme activity had to be 
quenched. For this purpose, three enzyme inactivation methods, i.e. heat-, perchloric acid- and 
liquid nitrogen- inactivation, were evaluated. Evaluation of each method included assessment of 
the effect of treatment on the phospholipid substrate and efficient enzyme inactivation. 
Inactivation assays were performed by incubating a volume of FPCL in 2.5% (m/v) lecithin at 
37°C. Prior to addition of enzyme to the phospholipid substrate, a 100 µL sample was collected 
as baseline control. The substrate was subsequently spiked with 441 ng enzyme per mL 
substrate. 100 µL aliquots were collected at 2 min intervals. Inactivation treatment was applied 
to each sample as follows: 
i. Heat inactivation: 
The collected samples were transferred to sample tubes pre-equilibrated to 90°C in an OMEG 
Scientific heating block. Each sample was heat treated for 15 min. 
ii. Method of perchloric acid inactivation: 
The collected sample was transferred to a sample tube containing 10 µL perchloric acid. 
Following inactivation, the acid was neutralized with 10 M KOH. The amount of KOH needed for 
neutralization was evaluated using pH indicator strips (Merck Darmstadt, Germany). Once the 
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optimal volume of KOH was established, the experiment was repeated and the FFA quantified 
as described. 
iii. Liquid nitrogen inactivation: 
The collected aliquots were rapidly transferred to plastic thin walled 250 µL polymerase chain 
reaction tubes and immersed in liquid nitrogen. After all aliquots were collected, the samples 
were heat treated for 15 min at 90°C. 
Following heat treatment, all samples were centrifuged at 3000 x g for 5 min and the FFA 
content of the supernatant was quantified using the NEFA HR FFA quantification kit as 
described previously. The results from each assay were compared in terms of linearity of the 
collected samples when plotted, as well as the FFA content of the baseline blank samples 
following treatment.  
5.4.1.3 Enzyme activity assay 
The hydrolytic activity of GCAT, using acetone washed lecithin, was quantified by adding 840 ng 
protein to a 2.5% (m/v) lecithin solution at 37°C in poly top glass vials. A 100 µL aliquot was 
collected at 0 min followed by aliquots at 2 min intervals for a total of 10 min. Enzyme activity in 
all the aliquots collected was completely inhibited as described in Section 5.3.1.2.iii. Following 
enzyme inactivation, the FFA content was quantified as previously described in Section 5.2.4.1. 
The FFA concentration was plotted as a function of time to yield individual rate equations. 
The same assay was used for kinetic analysis with SUVs consisting of DOPC or purified egg 
yolk lecithin (Sigma-Aldrich) as substrate. In these assays 1.2 mL SUV suspension of each 
substrate concentration was prepared, and 1 mL was used for each assay. Incubations were 
performed in 8x40 mm shell vials in an OMEG Scientific heating block maintained at 37°C. To 
the substrate solution, 500 ng protein was added and a total of six aliquots were collected at 
timed intervals starting with T0 (no enzyme). Rate equations were prepared as described above 
and kinetic analysis was performed using GraphPad Prism® 5 software. 
5.3.2 Acyl transferase assay 
For monitoring the transferase reaction catalyzed by GCAT, SUVs consisting of DOPC and 
cholesterol were prepared as described in section 5.3.1.1 to a final volume of 1.2 mL. In these 
assays, 26(27) - 14C cholesterol (53 mCi/mmol) was added as reaction tracer. Incubations were 
performed in 8x40 mm shell vials in an OMEG Scientific heating block maintained at 37°C.  
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After preparing the SUV substrate suspension, 1 mL was transferred to a chemically cleaned 
shell vial and equilibrated to 37°C for 10 min. Following equilibration, 210 ng protein was added 
and 6x100µl aliquots were collected starting at T0. The enzyme activity of each aliquot was 
terminated by the addition of 5 mL dichloromethane in 15 mL teflon-lined screw cap culture 
tubes. Prior to lipid extraction 300 µl dH2O containing 0.05% (
w/v) phenolphthalein and 1% (
w/v)
 
NH3OH was added to each sample to increase the visibility of phase separation. Lipids were 
extracted by mechanical shaking for 10 min using an IKA VXR Vibrax basic at 1500 RPM. Each 
sample was subsequently centrifuged at 3000 x g for 10 min. The aqueous phase of each 
sample was removed by aspiration and the residual solvent was evaporated under a stream of 
nitrogen at 50°C. The dried lipids were subsequently dissolved in 50 µl chloroform and 
separated using TLC.  
For analysis, 20 µL of each sample was applied to a 10 x 20 cm TLC plate and cholesterol and 
cholesteryl esters were separated with hexane containing 5% (v/v) ethyl acetate as mobile 
phase. The plates were developed by spraying with diluted sulphuric acid (50% (v/v)) as 
described in Section 5.2.2.2. Radiolabeled cholesterol and cholesteryl oleate spots 
(corresponding to standards) were excised, added to 4 mL scintillation fluid and counted in a 
liquid scintillation counter (Perkin Elmer Tri-Carb 2810 TR). Rate equations, for the formation of 
cholesteryl oleate, were prepared and the reaction rate, in mM/min, was determined. Units of 
activity was subsequently converted to µmol/min using Equation 5.1. Each assay concentration, 
used for Michaelis-Menten kinetic analysis, was performed in triplicate. 
                                   
Equation 5.1 Equation for the conversion enzyme activity, in mM/min, to µmol/min. 
5.3.3 Continuous assays using pNPB as substrate 
The activity of GCAT was continuously monitored spectrophotometrically at 400 nm and 37°C 
on a Biotek Powerwave 340 microtiter plate reader by the release of pNP from pNPB. The 
liberated pNP was quantified by comparison to a calibration curve prepared from a 10 mM pNP 
stock. Prior to each assay a known amount of FPCL (mg protein) was diluted with assay buffer 
(10 mM HEPES-buffer, 0.5 M NaCl and 0.1% Triton X-100, pH 7.0) to yield a maximal 
absorbance change of ≈1.0 AU/min. In our hands a 16 000-fold dilution of the FPCL stock (≈88 
ng protein) was sufficient for all samples assayed. The diluted enzyme solution was kept on ice 
when not in use, and was prepared fresh every two hours. The final assay volume for this 
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method was 200 µL and it was sufficiently sensitive to detect GCAT activity in milk samples 
dosed with 10 ppm FPCL. Milk samples were diluted 10 fold prior to the assay. 
Assay procedure:  
A calibration curve of pNP was prepared in the range between 0.001 and 0.2 mM (assay 
concentration), from a 10 mM pNP stock. Of each standard 10 µL was added to 190 µL assay 
buffer in a microtiter plate and the contents were mixed by swirling the plate in a figure of eight 
movement.  
Activity assay: 
The following volumes of reagents were added to the wells of a 96-well microtiter plate. At least 
four assay blanks were run in concord with the samples in order to determine the assay 
background absorbance. 
 Blank Sample 
Assay buffer 90 µL 90 µL 
Substrate solution 10 µL 10 µL 
After addition of the substrate solution the plate was swirled in a figure of eight movement to mix 
the contents of each well. Of the diluted enzyme solution/milk sample 150 µL was added to the 
well adjacent to the well containing the assay substrate to ensure similar temperature 
equilibration. The plate containing diluted enzyme and substrate solution was subsequently 
equilibrated to 37°C inside a thermostated plate reader. After 5 min equilibration the following 
was transferred to the wells containing assay buffer and substrate solution. 
 Blank Sample 
Assay buffer 100 µL 0 µL 
Enzyme solution 0 µL 100 µL 
Immediately after the equilibrated enzyme solution was added, the absorbance of each 
sample/blank was measured at 400 nm in 5 second intervals at 37°C for 1 minute using the 
Biotek Gen5 software. The pNP concentration for each data point was subsequently determined 
by comparison to a calibration curve. pNP formation (in mM) was plotted as a function of time, 
and rate equations were constructed. 
For kinetic analysis of GCAT, the same assay procedure was employed. However, a dilution 
series of pNPB substrate from 0.01 – 3.5 mM (assay concentration) was used instead of a 
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constant substrate concentration of 10 mM. Each substrate concentration was repeated in 
quadruplicate. Product formation was quantified by comparison to a calibration curve of pNP. 
The rate of product formation (mM/min) was subsequently converted to standard enzyme 
activity units (U) in µmol product formed per minute by using Equation 5.2. Specific activity was 
calculated using Equation 5.3. The calculated enzyme activity units were subsequently plotted 
against substrate concentration. Michaelis-Menten analysis was performed on this data using 
GraphPad Prism® 5 software.  
                                              
Equation 5.2. Equation for the conversion of reaction rate, in mM.min
-1
, to units of enzyme activity, in µmol.min
-1
. 
           
                                        
            
 
Equation 5.3. Equation for the conversion of units enzyme activity, in µmol/min, to specific activity in µmol/min/mg 
protein. 
5.3.4 Evaluation of FPCL for use in the Scania processing method 
Following the development of a facile and accurate GCAT activity assay the acceptability for the 
use of FPCL in the Scania processing method was evaluated in fat free buffered systems using 
the synthetic substrate pNPB. In these assays 1 mL Novo buffer* was spiked with 3 ppm FPCL 
and incubated at 65°C. Aliquots of 100 µL were subsequently collected at 0, 10, 20, 30, 60 and 
90 min. Collected samples were stored on ice until activity quantification. Residual enzyme 
activity was subsequently comparatively determined with pNPB as substrate using the microtitre 
plate assay described in Section 5.3.3. Unspiked buffer was used as experimental control. 
5.4 DATA ANALYSIS 
All experiments were performed at least in triplicate, unless stated otherwise, and the data 
presented as the mathematical mean. Data presentation, analyses and statistics were 
performed using GraphPad Prism® 5 software. 
                                                          
*
 Novo buffer: 2.7mM sodium citrate, 10 mM phosphate, 7.91 mM citric acid, 19.43 mM potassium hydroxide, 4.08 
mM magnesium chloride, 5.1 mM calcium chloride and 3.33mM sodium carbonate pH 6.5 
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5.5 RESULTS AND DISCUSSION  
5.5.1 Liquid chromatographic analysis 
For chromatographic analysis of milk lipids, lipid extraction is required. Before attempting 
chromatographic analysis of milk samples, three lipid extraction methods were evaluated and 
compared in terms of cholesterol recovery. With the use of radiolabeled cholesterol it was 
shown that extraction Method 3 recovered 94% of the labeled cholesterol compared to 79% and 
<10% for Methods 1 and 2 respectively. 
Lipid hydrolysis results in the formation of glycerol and FFA moieties. These moieties will not be 
extracted by hexane due to their more polar nature. As can be seen in Figure 5.1, extraction 
Method 1 yielded an extract containing fewer lipids which results in reduced peak overlapping. 
However, lipid hydrolysis also results in the hydrolysis of cholesteryl esters. This method of 
extraction is therefore only viable for use in total cholesterol quantification. Omission of 
saponification resulted in less of the total lipid being extracted. For these reasons extraction 
Method 3 was used for all subsequent extractions in preparation for GC and HPLC analysis. 
 
Figure 5.1 Comparison of extraction methods with HPLC-UV using a Waters Symmetry C18 column with methanol as 
mobile phase at 1 mL/min. 
The use of HPLC for quantitative purposes has been well established due to its ease of 
operation, reproducibility and accuracy. HPLC analysis has the advantage that cholesterol can 
be readily detected using a UV detector. However, the low maximum UV absorbance of 
cholesterol at 210 nm, severely limits the usable polar solvent range. With the exception of 
Cholesterol peak 
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acetonitrile, most polar solvents have UV cut-off values above 210 nm, resulting in high 
background absorbance and decreased resolution.  
The low polarity of long-chain cholesteryl esters furthermore results in limited solubility in polar 
organic solvents. This reduces the useable solvent range for HPLC analysis even further. A 
cholesteryl ester solubility assay was subsequently performed to evaluate possible polar 
solvents for separation of cholesterol and cholesteryl esters. From these studies, it was shown 
that both cholesteryl stearate and cholesteryl palmitate remains in solution when diluted from a 
10 mg/mL stock in ethanol. Ethanol was subsequently used as the main solvent for RP-HPLC 
analysis. Figure 5.2 shows the retention of a cholesterol standard by C18 columns from different 
manufacturers. Ethanol, isopropanol and water (93:3:5) was used as mobile phase. As can be 
seen, the retention of cholesterol varies significantly between different columns under similar 
conditions. Increased retention times would result in an increased run duration and solvent 
usage. In order to reduce overall run duration, the Waters Atlantis column was used for all 
subsequent analyses. 
 
Figure 5.2 Retention profiles for cholesterol on C18 columns from different manufacturers. The columns tested were 
Waters Symmetry, Phenominex Luna(2) and a Waters Atlantis. 
A standard mixture consisting of cholesterol, cholesteryl stearate and cholesteryl palmitate was 
subsequently injected (4 µg) using the same solvent as described above. The result for this 
separation is depicted in Figure 5.3. As can be seen, both cholesteryl esters are strongly 
retained. As a result, the peak shape and resolution is significantly reduced. In order to improve 
peak shape and decrease retention, mobile phase water was substituted with methanol. This 




Figure 5.3 HPLC separation of a standard mix containing 200 µg/mL cholesterol and cholesteryl ester standards with 
ethanol isopropanol and water (93:3:5) as mobile phase. A Waters Atlantis C18 column was used for separation. 
Since the HPLC method is intended for the separation and quantification of cholesterol and 
cholesteryl esters in milk samples, fat free milk, spiked with standards, were used as sample 
matrix in subsequent studies. Figure 5.4 depicts the HPLC separation of fat free milk spiked with 
0.2, 0.1 and 0.01 mg/mL (m/v) of the standard mixture as described previously. From this figure it 
can be seen that the overall separation profile is similar for each sample with the exception of 
the cholesterol and cholesteryl standard peaks  
 
Figure 5.4 HPLC analysis of fat free milk spiked with cholesterol and cholesteryl ester standards. HPLC conditions: 




The HPLC method was validated against a microtiter plate assay using Liebrman-Burchard 
reagent as will be described in the following section. This assay was selected due to its 
sensitivity, and because samples are extracted and prepared for analysis in the same manner. 
These results suggest that although analysis of milk lipids result in high background, this can be 
compensated for using fat free milk as matrix.  
5.5.2 Cholesterol quantification using a modified Lieberman-Burchard reagent 
Cholesterol quantification using the assay described by Kim and Goldberg155, with a modified 
LB reagent, was successfully scaled to a micro-assay with a final volume of 200 µL. When 
adding LB reagent directly to aqueous samples, the reaction mixture reacts violently resulting in 
a reduction of assay sensitivity. Consistent with this, Kim and Goldberg155 observed a 50% 
reduction in sensitivity when 8% (v/v) water was added to each assay. This is mainly due to the 
acidic nature of the LB reagent. For this reason, lipid extraction and suspension in an organic 
solvent, such as hexane, is required in order to accurately quantify cholesterol in aqueous 
samples such as milk. 
As can be seen in Figure 5.5, performing a spectral scan of LB reagent containing a cholesterol 
standard, following 20 min incubation at 37°C, indicated that LB reagent has an optimal 
absorbance at 615-625 nm when incubated with cholesterol. This result was consistent with 
previous descriptions of assays using LB reagent155,159. The absorbance of all subsequent 
assays was consequently measured at 620 nm. 
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Figure 5.5 Spectral scan (480 – 800 nm) of LB reagent containing a cholesterol standard in a final assay volume of 
200µl following 20 min incubation at 37°C. 
The effect of incubation time was subsequently evaluated in order to determine if the final assay 
volume has an effect on assay sensitivity. As can be seen from Figure 5.6.A, maximal 
absorbance for the microtiter plate assay was reached after 25 min incubation at 37°C. After this 
point the absorbance steadily decreased at a rate of 0.0007 absorbance units per min. This 
was, however, not the case for a final assay volume of 1 mL containing the same ratio (1:4) 
cholesterol standard: LB reagent. As can be seen in Figure 5.6.B, maximal absorbance was 
achieved after 10 min incubation at 37°C. After 10 min, the absorbance decreased at a rate of 
0.0092 absorbance units per min. Since the optimal incubation time was not constant when 
different assay volumes were compared, this result suggests that this assay does not scale in a 
linear fashion and optimization for each assay volume is essential. 
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Figure 5.6 Comparison of optimal incubation time for the micro-assay (A) and assay with a final volume of 1 mL (B). 
Each assay was performed with 4µg cholesterol standard and incubated at 37°C for the times indicated and 
determined at 620nm. 
The ratio of sample to LB reagent did not have an effect on the linearity of the assay. As can be 
seen from Figure 5.7, the regression line formula and R2 was not significantly affected by 
variations in the ratio of standard to LB reagent. A linear increase in absorbance was observed 
for an increase in the ratio of cholesterol to LB reagent. 
 
Figure 5.7 The effect of sample to LB reagent volume on assay linearity and final absorbance. 
In order to validate the results obtained, the cholesterol content of an egg yolk extract (prepared 
by Method 3 in Section 5.2.1 ) was determined using each assay (20 µl and 40 µl sample). Both 
assays yielded a final cholesterol concentration of  498 µg/mL egg yolk extract. Based on the 
y = 0.0002x - 0.0021 
R² = 0.9982 
y = 0.0002x + 0.0106 
R² = 0.9959 
y = 0.0003x + 0.0021 





























results described above, all subsequent microtiter plate assays were performed using the 
conditions described in Table 5.2 . 
Table 5.2 Volumes and incubation conditions for cholesterol quantification in lipid extracts. 
Volume sample (µL) 20 
Volume LB reagent (µL) 160 
Incubation time (min) 25 
Incubation temperature 37°C 
The assay described was linear in a cholesterol concentration range from 26 µM to 26 mM and 
can be used for the simultaneous quantification of multiple lipid extracts. This method was 
furthermore not affected by cholesteryl esters present in the extracted sample. 
5.5.3 Enzyme coupled GCAT product quantification assays 
5.5.3.1 Free fatty acid quantification 
As discussed in Chapter 3, the FFA content of samples can be quantified using titemetry or 
chromatographic analysis. However, these methods require relatively large sample volumes 
and/or individual standards for each FFA present. The use of enzyme-based assay kits enables 
the simultaneous quantification of multiple samples without the need for sample extraction and 
individual FFA standards.  
The NEFA HR kit is intended for use with automated analysis systems such as the  
Konelab 20XT Clinical Chemistry Analyzer. For this study the kit protocol was adapted for use in 
a microtiter plate based assay by reducing the individual reagent volumes. The efficiency of this 
adaptation was evaluated as the regression fit of an oleic acid standard dilution series. As can 
be seen from Figure 5.8, the NEFA HR(2) kit was successfully adapted to a microtiter plate 
based assay for a concentration range between 0.05 and 1 mM oleic acid. Using this assay, the 
FFA content of low sample volumes (10 µl) could be accurately quantified in a two-step 10 min 
spectrophotometric assay.  
Due to the specificity of the enzymes present, only FFA is quantified without interference from 
lipids present in the sample. The use of the NEFA HR(2) assay enabled quantification of 
enzyme activity in small reaction volumes, thereby reducing the quantity of substrate required 
during activity assays. This kit could furthermore be used for the quantification of total FFA in 
milk samples obtained from pilot- or full-scale FPCL trials. These results will, however, be 
discussed in more detail in the following sections.  
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Figure 5.8 Standard curve produced by serial dilution of a 1 mM oleic acid standard. The regression line does not 
pass through zero due to low-level background absorbance. 
5.5.3.2 Cholesterol/Cholesteryl ester quantification 
Although the cholesterol content of milk samples could be accurately quantified using the LB 
assay described previously, this assay requires lipid extraction prior to quantification. 
Additionally, in order to quantify total cholesterol (cholesterol and cholesteryl esters), ester 
hydrolysis is required prior to analysis. Total cholesterol quantification, using LB reagent, is 
therefore time consuming and labor intensive. The use of enzyme based kits allows for the rapid 
quantification of both cholesterol and cholesteryl esters in a microtiter plate fluorescent assay. 
This assay proved sufficiently sensitive to quantify cholesterol and cholesteryl esters in milk 
samples. However, although activity assays could be performed successfully with the use of the 
cholesterol/cholesteryl ester quantification kit, these kits are expensive (up to $5 per well). The 
use of quantification kits were therefore limited to analysis of milk samples collected from pilot- 
and full-scale FPCL trials. 
5.5.3.3 Quantification of cholesterol and cholesteryl esters in milk samples obtained from FPCL 
trials 
Subsequent to all pilot scale trials described in Section 3.2.2.1, the cholesterol and cholesteryl 
ester content of the collected samples were determined as described in this section. The 
average cholesterol conversion data for these trials are depicted in Figure 5.9. The % 
cholesterol conversion was calculated as the percentage difference between total cholesterol 
and free cholesterol subsequent to UHT treatment. As can be seen, the conversion of 
y = 0.8304x + 0.0102 




























cholesterol to cholesteryl esters was similar for all trials. An average cholesterol conversion of 
68% was achieved for all the trials performed. From this figure an increase in the cholesteryl 
ester of the control samples can be observed. However, milk cholesterol content is known to 
vary with the season. This result is therefore most likely due to lipid variations with a change in 
season. 
 
Figure 5.9 Cholesterol conversion data from pilot trials performed in 2012. The cholesterol content of each sample 
was determined in duplicate. 
Figure 5.10 depicts the cholesteryl ester content of each sample collected from the factory trial 
described in Chapter 4 Section 4.2.2.2. The cholesteryl ester content is calculated as the 
amount of cholesteryl ester in relation to total cholesterol. As can be seen, the cholesteryl ester 
content again did not differ substantially, irrespective of milk fat content and incubation time. 
Although this would suggest that maximal cholesterol conversion had been achieved, this was 
not reflected by a substantial increase in the FFA content as depicted in Figure 5.11. 




Figure 5.10 % Cholesteryl ester of each sample calculated as the amount cholesteryl ester in relation to total 
cholesterol content. The X axis depicts the sample collection times for each duplicate. 
The FFA quantification method described in Section 5.2.4.1 measures FFA in molar 
concentrations. Percentage FFA was subsequently calculated using the molecular weight of 
oleic acid as reference. The values depicted in Figure 5.11 are therefore estimates. In this figure 
the red line indicates the maximal allowed amount of FFA. As can be seen addition of FPCL did 
not substantially increase the milk FFA content, even after prolonged incubation (07:26 – 
10:11). 
 
Figure 5.11 Comparison of the % FFA of the collected samples. In this figure samples were duplicate samples were 
collected 10 min and 2.5h from each other. The maximal suggested % FFA before the product loses commercial 
appeal is estimated at  0.25 % FFA. 
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5.5.4 Enzyme activity assays 
FPCL, containing GCAT as the active enzyme, is intended for industrial application. A rapid and 
accurate assay for activity quantification is therefore essential to ensure optimal dosage. In 
order to increase economic viability, this assay should also allow for high throughput screening 
of multiple samples simultaneously. As discussed in Chapter 3, various methods are available 
whereby the activity of GCAT may be quantified. However, these methods are labour intensive, 
time-consuming and often rely on the use of radiolabeled substrates.  
The use of synthetic substrates enables continuous reaction monitoring, yielding more accurate 
activity quantification. However, it has not yet been shown if the units of enzyme activity are 
similar when compared to assays using natural substrates. For this reason, it is important to 
compare these assays and determine the kinetic parameters of GCAT with the use of different 
substrates. Comparison of the kinetic parameters would give an indication if pNPB may be used 
as substrate for accurate activity quantification. 
5.5.4.1 Phospholipase activity assay using pNPB as substrate  
Due to the labour intensive nature of enzyme activity determination using lecithin as substrate, 
synthetic substrates for lipase enzyme activity monitoring were evaluated. Nitrophenol 
substrates are well-known for their use in the enzyme activity quantification of various enzymes 
such as lipases, neutral phosphatases, β-galactosidase and α-amylases160–162. Furthermore, 
pNPB has been shown previously to be an effective substrate for the GCAT enzyme78. During 
its reaction with pNPB, GCAT hydrolyzes the ester bond yielding nitrophenol and a free fatty 
acid. Under basic conditions, the resulting nitrophenol is deprotonated to form para-
nitrophenolate which has a strong absorbance at 400nm.  
The use of pNPB therefore enables the continuous monitoring of product formation. Due to the 
stoichiometric ratio of nitrophenol to free fatty acid (1:1), enzyme activity is defined as the 
amount of enzyme that liberates 1 nmol of nitrophenol per minute under assay conditions148,163. 
However, this definition of enzyme activity is generic and does not necessarily apply to all 
enzymes assayed. The definition of a single unit of enzyme activity, using pNPB as substrate, 
should therefore be defined by comparison to assays using natural substrates. 
Continuous assays are more accurate, reproducible and less time-consuming than end-point 
style assays. A microtiter plate assay was consequently developed whereby the hydrolytic 
activity of GCAT could be quantified using pNPB. In order to determine the pNPB concentration 
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at which substrate saturation is reached, full kinetic analysis was performed with pNPB 
concentrations ranging from 0.01 – 3.5 mM spiked with a diluted FPCL preparation containing 
88.44 ng protein. In Figure 5.12 it can be seen that saturation was reached at ≈1mM pNPB. 
Michaelis-Menten kinetic analysis of the data obtained yielded a maximum specific reaction 
velocity of 292.4 µmol.min-1.mg protein-1 and a Michaelis constant (Km) of 0.09 mM. Subsequent 
activity assays were therefore performed with 10 mM pNPB to ensure saturation. 
 
Figure 5.12 Michaelis-Menten kinetic analysis of the lipase activity of GCAT using the assay using pNPB as 
substrate as described in the text (N = 3, R
2
 = 0.98). 
A unit of enzyme activity, for the continuous microtiter plate assay, was subsequently defined by 
comparison to assays performed using lecithin as substrate. The results of activity assays using 
both lecithin and pNPB are presented in Table 5.3. As can be seen, the values for pNPB did not 
correlate well with the results from the assay performed with lecithin when it was assumed that 
the definition for a unit of activity was the same for both assays (pNPB (1)). Based on these 
results, the definition for a single unit of enzyme activity was adapted as follows: 
Definition: 1 Unit of enzyme activity, when using pNPB as substrate, is the amount of enzyme 
(in mg) which will produce 0.250 µmol pNP per minute under assay conditions. 
Table 5.3 Comparison of enzyme activity determined with the use of lecithin and pNPB. Total enzyme activity per mL 
FPCL is calculated by multiplication of U with the total amount of protein present in FPCL (14.74 mg/mL). 
Substrate Reaction rate mM/min Reaction rate µmol/min µmol/min/mg (U) 
U/mL 
FPCL 
Lecithin 0.0188 0.056 66.96 987.05 
*
pNPB (1) 0.1200 0.024 272.73 4020.00 
*
pNPB (2) 0.1200 0.024 68.18 1005 
* pNPB 1 was calculated using the standard definition for a unit of enzyme activity while pNPB (2) was calculated 
using the adapted definition for a single activity unit described above. 
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Applying this definition (pNPB 2) yielded similar activity results when compared to the assay 
performed using lecithin as substrate. Although the data presented here indicate the results 
from a single assay, with three replicates, these results were highly reproducible. This data 
suggests that these assays may be used interchangeably for enzyme activity screening. The 
results were furthermore consistent with the activity data stipulated in the FPCL specification 
sheet presented in Addendum A. 
5.5.4.2 GCAT kinetic analysis 
As mentioned previously, to the best of our knowledge, no kinetic data for the GCAT enzyme 
have been published. Familiarity with the kinetic parameters, Km and Vmax should provide more 
evidence if pNPB may be used as a substrate for GCAT activity screening. If this is shown to be 
the case, the newly developed assay may also be used to determine optimal dosage 
concentration and incubation time during industrial application of FPCL. 
The natural substrates for GCAT have no measurable chromogenic properties. A discontinuous 
assay was therefore developed in order to study the kinetic characteristics of GCAT. In this 
assay GCAT was incubated with a SUV substrate suspension consisting of DOPC or purified 
egg yolk lecithin. To enable measurement of the transferase activity, cholesterol was 
incorporated into the SUV as described in the methods section. Aliquots were subsequently 
collected at timed intervals and the enzyme activity was quenched. Enzyme activity was 
monitored by the production of FFA or cholesteryl ester. After development of the assay, SUV 
preparation was evaluated and optimized. 
As mentioned earlier, various methods have been described to inactivate the enzyme activity. 
These methods often include the use of acids, such as trichloroacetic- or perchloric acid. 
However, as can be seen in Figure 5.13 the use of perchloric acid resulted in substrate 
phospholipid hydrolysis and, subsequently, high levels of FFA. As a result, FFA liberation was 
not linear, and the results of assays inactivated with acid could not be used. Since GCAT is heat 
sensitive and loses enzyme activity when exposed to temperatures in excess of 80°C, heat 
inactivation was subsequently evaluated. From these studies it was shown that enzyme activity 
was destroyed by heat treatment. However, FFA production was once again not linear indicating 
that enzyme activity was not destroyed in a consistent manner. Each aliquot was therefore first 
flash-frozen, using liquid nitrogen prior to heat inactivation. From Figure 5.13 it can be seen that 
using this method FFA liberation was more linear. Enzyme inactivation by flash freezing and 
heat treatment (Section 5.3.1.2 Method iii) was therefore used for all subsequent assays. 
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Figure 5.13 Comparison of enzyme inactivation methods as evaluated by the linearity of FFA liberation. 
The transferase activity of GCAT was evaluated using SUVs consisting of DOPC, cholesterol 
and radiolabeled cholesterol as substrate. The newly developed assay was sufficiently sensitive 
to monitor transferase activity at substrate levels as low as 10 µM cholesterol and phospholipid. 
During earlier studies, performed by Buckley et al.39, it was shown that the acyltransferase 
activity of GCAT is maximal when equimolar concentrations of cholesterol and phospholipid is 
used. The transferase activity of GCAT was therefore initially monitored with SUV suspensions 
consisting of equimolar concentrations of cholesterol and DOPC. During these assays the 
vesicle suspension was sonicated for a total of 40 min.  
Kinetic analysis of the transferase activity of GCAT, using SUVs consisting of equimolar 
concentrations of cholesterol and DOPC, is depicted in Figure 5.14. From this figure it can be 
seen that the transferase activity of GCAT is inhibited at substrate concentrations in excess of 
0.250 mM. The decrease in transferase activity coincided with a decrease in reproducibility of 
the data. Excluding the data of substrate concentrations above 0.250 mM and extrapolating the 
curve yielded an apparent Km of 0.071 mM and a Vmax = 52.67 µmol/min/mg protein. Using this 
data, the total activity of FPCL was calculated to be 776 units/g FPCL. However, since 





























Figure 5.14 Michaelis-Menten kinetic analysis of GCAT using a substrate consisting of equimolar concentrations of 
DOPC and cholesterol (N = 3). The red line indicates the point, at 0.250 mM, where inhibition starts. 
The effect of SUV composition on enzyme catalysis was subsequently investigated. As 
discussed in Chapter 3, cholesterol cannot form vesicles independently of phospholipid. 
Therefore, in order to study the effect of cholesterol on enzyme catalysis independently from 
phospholipid, SUVs consisting of 0.6 mM DOPC and varying concentrations of cholesterol were 
prepared. A preliminary study was conducted wherein single assays were performed. The result 
from this study is presented in Figure 5.15 where the x-axis represents the ratio of cholesterol to 
phospholipid. An inhibition profile was again observed. Moreover, enzyme catalysis is inhibited 
at cholesterol/phospholipid ratios above 1:1. Previous studies by New136 suggests that 
cholesterol to lipid ratios of 1:1 should yield optimal vesicles since cholesterol is incorporated 
intermediate to each lipid molecule, forming ordered structures at these ratios. The inhibition 




Figure 5.15 Results of a preliminary study of wherein the effect of substrate composition on GCAT activity was 
investigated (N = 1). 
Although the data presented were obtained using SUV suspensions consisting of DOPC and 
cholesterol, similar results were obtained using purified egg yolk lecithin. The result may be due 
to various factors, however, the most likely reasons is either the inability of DOPC to form 
correctly structured SUVs at concentrations in excess of 0.25 mM or allosteric product inhibition. 
Attention was therefore shifted to evaluation of vesicle formation.  
In order to evaluate the factors governing vesicle formation, SUVs were prepared as described 
previously without addition of cholesterol. Since milk contains various phospholipid species, 
purified lecithin from egg yolk was used as substrate for structural and kinetic analysis. SUVs 
consisting of egg yolk lecithin were prepared as described in the previous section by 40 min 
sonication. Figure 5.16 depicts the results from a lipase activity assay using SUVs prepared with 
0.2 mM lecithin spiked with 1 µg protein. As can be seen from this figure, the initial FFA 
concentration is 57% of the total phospholipid concentration prior to addition of the enzyme. 
Furthermore, although the initial velocity of the first replicate appears linear, this result was not 




Figure 5.16 GCAT activity assays with SUVs consisting of purified egg yolk lecithin as substrate. 
The high levels of initial FFA may be due to two factors namely, enzyme over-dosage or 
hydrolysis of the phospholipid substrate during sonication. Eklund164 suggested that sonication 
up to 60 min does not result in significant phospholipid hydrolysis. The effect of enzyme 
concentration was therefore evaluated using SUVs prepared in the same manner as described 
previously with 0.5 mM lecithin. The substrate suspension was subsequently spiked with 420 
and 210 ng protein respectively. As can be seen from Figure 5.17, the reduction of spike 
concentration did not have a significant effect on assay linearity and initial FFA concentration. 
This is especially evident since the 210 ng spike had a higher initial FFA concentration than the 
assay spiked with 420 ng protein. Furthermore, there was no significant formation of FFA even 
after a prolonged incubation period. These results suggest that the vesicular structure is 




























Figure 5.17 Evaluation of the effect of enzyme spike concentration on assay linearity. 
The effect of sonication time on vesicular formation was consequently investigated by sonication 
of 0.25 mM lecithin suspensions for different time periods. The SUV suspension was 
subsequently spiked with 1 µg protein and aliquots were collected at 2 min intervals. As can be 
seen from Figure 5.18, sonication time had a substantial effect on assay linearity. However, 
from the initial FFA values presented in Table 5.4 it can be seen that sonication times in excess 
of 20 min results in substantial hydrolysis of the phospholipid substrate. Sonication times of 10 
and 20 min did not differ substantially with respect to initial FFA concentration and final assay 
reaction rate. However, there was still a substantial initial increase in FFA concentration after 
addition of enzyme. These results suggest over-dosage of the substrate suspension with 
enzyme. Based on these results, total sonication time was reduced from 40- to 20 min and 
enzyme spike concentration was reduced to 515 ng per mL substrate. Lecithin concentrations 






























Figure 5.18 Effect of sonication time on the linearity of an activity assay using 0.250 mM substrate. 
Table 5.4 Comparison of assay linearity in response to an increase in total sonication time. 
Sonication time (min) Initial FFA (mM) Reaction rate mM/min 
10 0.042 0.0126 
20 0.042 0.0132 
40 0.078 -0.0034 
Figure 5.19 depicts the results from kinetic analysis using SUVs consisting of both lecithin and 
DOPC respectively. From this figure it can be seen that the phospholipase activity of GCAT 
followed an inhibitory profile at substrate concentrations in excess of 0.17 mM, irrespective of 
the phospholipid species used. Previous results suggest that the initial FFA content of substrate 
suspensions plays a major role in assay linearity and quality. The FFA content of substrate 
suspensions, prior to the addition of enzyme, was subsequently quantified and shown to be 
below 2 µM. It therefore appears that 20 min sonication still results in the structural 
disintegration of SUVs. The total sonication time was consequently reduced to from 20- to 10 































Figure 5.19 Comparison of SUV composition by means of kinetic analysis. Each point on the graph indicates a single 
assay. 
A reduction in the total sonication time had a major effect on assay linearity and reproducibility. 
As can be seen from Figure 5.20, a decrease in sonication time eliminated the inhibition profile 
previously observed. However, this resulted in a concurrent reduction in overall reaction 
velocity. Furthermore, a general decrease in reaction velocity was observed for substrate 
concentrations up to 0.25 mM. 
 
Figure 5.20 Kinetic analysis of GCAT lipase activity with SUVs consisting of purified egg yolk lecithin sonicated for a 
total of 10 min (N = 3, R
2
 = 0.93). 
Although a reduction in overall initial velocity was observed, kinetic analysis of GCAT was 






































prepared by sonication for 10 min. When plotted, the data yielded a kinetic profile consistent 
with Michaelis-Menten catalysis. Kinetic analysis of the data yielded a Vmax of 15.84 and a Km of 
0.190 mM. Therefore, although a reduced initial reaction rate was observed, the Vmax value 
obtained was higher than the highest reaction velocity from Figure 5.19, 12.17 µmol/min/mg 
protein. 
The kinetic parameters obtained from the assays described, using both pNPB and lecithin, are 
presented in Table 5.5. It is expected that the Km for each substrate would differ, and this is 
certainly the case. In order to prove that pNPB may be interchangeably used as substrate for 
activity monitoring of GCAT, the Vmax values should correspond. From the data presented in 
Table 5.5, it can be seen that the Vmax values differ substantially. As a result, the final activity 
per gram FPCL differs by 76%. However, the vesicular structure was shown to be compromised 
during preparation of SUVs, resulting in a reduced reaction rate. The values obtained during 
kinetic characterization using SUVs consisting of lecithin may therefore be an underestimation 
of actual hydrolytic activity. 
Table 5.5 Comparison of kinetic parameters and final enzyme activity per mL FPCL obtained using pNPB and lecithin 
as substrate. 
Assay substrate Km Vmax Total units per gram FPCL 
pNPB 0.09 292.40 1005.0 
Lecithin 0.19 15.84 233.50 
Since it was shown that excessive sonication results in the inhibition of enzyme catalysis at 
substrate concentrations above 0.2 mM, even in the absence of cholesterol, the transferase 
reaction catalyzed by GCAT was reevaluated. For these assays the same assay procedure 
described earlier was used. Sonication time was reduced from 40- to 20 min since sonication 
times below 20 min did not yield translucent SUV suspensions. 
From the results presented in Figure 5.21 it can be seen that, as was the case with 
phospholipase assays, a reduction in the total sonication time resulted in elimination of the 
inhibitory profile of enzyme catalysis for the transferase reaction. However, enzyme saturation 
could not be achieved with substrate ratios between 0.05:1 and 2.5:1 (cholesterol: 
phospholipid). A further increase in the cholesterol content of SUVs resulted in a loss of 
liposomes as observed by a rapid decline in enzyme activity. The data obtained was 
extrapolated and the apparent Km and Vmax was determined to be 2.83 mM and 102 
µmol/min/mg protein respectively.  
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Figure 5.21 Kinetic analysis of the transferase activity of GCAT using optimized substrates (N= 3). 
5.5.5 FPCL application analysis 
This section describes application of the newly developed pNPB activity assay in the evaluation 
of the applicability of FPCL in dairy UHT processing. 
5.5.5.1 Evaluation of the applicability for the use of FPCL in the Scania processing method 
During the production of 2% milk for commercial purposes using the Scania method, the fat 
content of raw milk is reduced from  3.8% to 2% by an in-line standardization process yielding 
2% milk and  40% fat/cream. In this process the whole milk temperature is increased to 
between 62 and 64°C in order to guarantee high quality cream. This holding temperature is 
sufficient to increase milk-fat fluidity and inactivate native milk lipase enzymes, reducing 
hydrolysis of free fat. The optimum holding time for this process is between 15 and 30 min prior 
to pasteurization. In order to prevent excessive FFA formation, the holding time, including filling 
and emptying, should not exceed four hours165. Excessive production of FFA by lipase enzymes 
reduces the beating ability of cream, and should thus be avoided.  
As described in Chapter 2, GCAT is active at water-lipid interfaces. The enzyme would therefore 
be present in the cream fraction after separation from whole milk during processing. For 
successful application, using the Scania method, FPCL should be fully inactivated during 
holding at 62-64°C. Retention of FPCL activity after holding will result in excessive FFA 
production, thereby reducing the commercial value of the cream. Inactivation studies were 
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therefore conducted at 65°C in Novo buffer. In these studies a buffered system was used since 
this allowed for low-level detection of GCAT activity without interference from milk lipids.  
 
Figure 5.22 The effect of prolonged incubation of FPCL at 65°C in Novo buffer on GCAT activity. 
As can be seen in Figure 5.22, incubation at 65°C for 90 min resulted in a significant (ca. 52%) 
reduction in enzyme activity. However, when compared to the control sample, it can be seen 
that enzyme activity was retained even after prolonged incubation. These results suggest that 
FPCL cannot be used for processing using the Scania method since residual GCAT activity is 
retained.  
5.5.5.2 Evaluation of FPCL activity subsequent to UHT processing 
During UHT processing the activity of GCAT is irreversibly inhibited. If enzyme activity is 
retained in the final product, excessive FFA production would lead to rapid product deterioration. 
In order to ensure that UHT processing effectively inhibited the enzyme, activity assays were 
performed on milk samples collected from the factory trial described in Chapter 4 Section 
4.3.2.2. Enzyme activity was monitored using the assay described in Chapter 5 Section 5.3.3. In 
these assays fresh pasteurized milk was spiked with 10 ppm FPCL as a positive control while a 
spiked sample boiled at 90°C for 10min was used as negative control.  
The results from these studies are depicted in Figure 5.23 below. In Figure A the activity of the 
GCAT enzyme was determined in collected samples using the newly developed pNPB assay. 
Figure B shows that enzyme activity can be detected at dosage levels of 10 ppm when 
compared to a no-enzyme control. From the figures it is clear that the GCAT enzyme was 
completely inhibited in all samples following thermal processing. Due to the low levels of dosage 
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and the complete inactivation following UHT treatment, residual GCAT will not play any 
significant role in the final product.  
 
Figure 5.23 Residual enzyme activity remaining following thermal processing at 142°C for 6 seconds for (A) UHT 
processed milk samples collected from the factory trial performed at Dewfresh. (B) Spiked and unspiked fresh 
pasteurized milk used as assay controls. 
5.6 CONCLUSION 
This chapter described the evaluation of techniques for the quantification of GCAT reaction 
products and its use in the development of an enzyme activity assay. Activity screening of 
GCAT have traditionally been determined using SUVs consisting of phosphatidylcholine and 
cholesterol as substrate coupled with scintillation detection. Although accurate, these methods 
are labour intensive and require specialized instrumentation. Furthermore, it is clear from the 
data presented that the organizational parameters of SUVs greatly affect the enzyme reaction 
rate.  
Although the data presented did not yield accurate kinetic data, it was shown that various 
parameters during the preparation of SUVs influence enzyme catalysis. It was furthermore 
shown that the initial reaction rate of GCAT, when using SUVs as substrates, is greatly affected 
by the sonication time during SUV preparation. This fact has not been reported previously. 
Although 10 min sonication yielded translucent SUV suspensions, the initial reaction rate was 
significantly lower than that of similar suspensions prepared with 20 or 40 min sonication. On 
the other hand, extensive sonication (40 min) yielded a reduced reaction rate at substrate 
concentrations in excess of 0.250 mM. It was found that sonication for 20 min yielded the best 
results during kinetic studies although maximal velocity is was not achieved. 
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The use of both SUVs and pNPB as substrates for reaction monitoring of GCAT have been 
described previously40,78. However, to the best of our knowledge, a kinetic study of the GCAT 
reaction using either substrate has not been described in literature. The previously described 
activity assays are furthermore not appropriate for kinetic studies due to the end-point styled 
approach. These studies also did not include a thorough investigation into substrate preparation 
and vesicle formation. 
The current study is the first account wherein the available assays for GCAT activity, using 
SUVs as substrates, have been adapted, and optimized, to discontinuous assays for the kinetic 
characterization of both the reactions catalyzed by GCAT. Furthermore, although further 
investigation is needed, the data obtained from these studies provide evidence for the two step 
reaction mechanism proposed by Hilton and Buckley82 (Chapter 3, Section 3.3.2). Disruptions in 
the three dimensional structure of the SUVs, such as that caused by phospholipid hydrolysis 
during sonication, may result in shielding of phospholipid head groups. This would reduce 
enzyme-head group interactions ultimately resulting in a reduced enzyme reaction rate. This 
scenario is supported by the finding that a reduction in sonication time and  
cholesterol: phospholipid ratios in excess of 2.5:1, resulting in a reduction in SUV formation, 
also resulted in a decrease in enzyme reaction rate.  
This study furthermore provides the first description of a microtiter plate assay, using pNPB as 
substrate, which may be used for the facile and accurate monitoring of FPCL enzyme activity for 
commercial application. Although the kinetic data obtained could not substantiate the use of 
pNPB as sole substrate for activity monitoring, it was shown, using food grade lecithin as 
substrate, that assays using pNPB and lecithin may be used interchangeably during reaction 
monitoring of GCAT in FPCL. Furthermore, upon request from DuPont® Industrial Biosciences, 
France, the newly developed microtiter plate assay has been submitted for validation to replace 
the current method of activity assay. Once validated by DuPont® scientists, the described assay 
will be implemented as the new global standard operating procedure (S.O.P) for commercial 
FPCL activity assay, replacing the current assay. 
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CHAPTER 6  
GENERAL DISCUSSION AND CONCLUSION 
The past 200 years have seen great advances in food safety. Thermal processing of dairy 
products prior to consumption is undoubtedly one of the most significant of all. Although the 
evidence is circumstantial, the infant mortality rate fell dramatically following the implementation 
of thermal processing of milk2. Today ultra-high temperature (UHT) processing of milk yields a 
product which is not only high in nutritional value but also has the added benefit of an extended 
shelf life when stored at ambient temperatures. However, as should be clear from the preceding 
sections, production of UHT milk is a difficult exercise. Temperature induced fouling increases 
the overall cost of thermal processing by increasing energy consumption and plant down-time. 
The need for hazardous cleaning chemicals, such as caustic soda and acetic acid, is 
furthermore harmful to the environment. Because of these difficulties, the overall production cost 
of UHT milk is increased, limiting its availability in rural areas where it is most needed. 
Consequently, fouling, and the prevention thereof, has been exhaustively investigated4–6. 
Although great advances have been made in the reduction of fouling during UHT processing, 
mainly by optimization of the processing parameters, fouling is still a major problem. The use of 
enzymes in milk and dairy products has enjoyed limited success in the past. However, addition 
of the bacterial enzyme, glycerophospholipid cholesterol acyltransferase (GCAT) to raw milk 
prior to thermal processing has shown promise. The results presented in the current study 
suggests that the correct use of the commercial enzyme preparation, FoodPro® Cleanline 
(FPCL), can increase thermal processing duration by up to 50%. However, preliminary trials 
indicated that the current methods used for quantification of GCAT reaction products, 
cholesteryl ester and free fatty acids, are not satisfactory for quality control purposes. Optimal 
enzyme activity can furthermore not be guaranteed upon delivery at the client since activity 
testing facilities are limited to Europe, Asia and the Americas. In order to ensure successful 
commercial application, the methods for quality control needed to be re-evaluated and 
alternatives offered.  
Enzyme catalysis is highly specific. As a result, the quality of the final product can be 
manipulated by adjusting enzyme dosage strength. If the mechanistic characteristics of the 
enzyme used are known, this information can be used to predict the extent of enzyme catalysis 
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following incubation. Conversely, if kinetic data for the GCAT enzyme could be produced, this 
information could be used for the development of a dosage model whereby final product 
cholesteryl ester and FFA content can be predicted. Availability of such a model would greatly 
increase the marketability of FPCL since this will allow product tailoring according to the needs 
of the client. This data may also be used for the validation of newly developed assays. However, 
assays for the study of the catalytic mechanism for GCAT have not been described previously. 
For this purpose, accurate methods for the quantification products of GCAT catalysis are 
crucial. Furthermore, the initial studies conducted illustrated the need for a facile activity assay 
whereby GCAT activity in FPCL can be validated. 
Therefore, the aim of this thesis was to evaluate methods available for quantification of GCAT 
reaction products. Apart from its uses for quality control purposes, these methods were also 
employed during the development of an activity assay whereby the kinetic mechanism of GCAT 
catalysis could be studied. The use of water soluble nitrophenol substrates for GCAT activity 
monitoring have been described previously78. Para-nitrophenol butyrate was subsequently used 
as substrate for the development of a rapid, reliable and practical assay for FPCL activity 
validation. During validation of this newly developed assay, the kinetic parameters obtained 
from kinetic studies were compared to that obtained from kinetic studies using pNPB as 
substrate. Additionally, the activities obtained from this assay and assays performed using food 
grade deoiled soy lecithin as substrate was compared.  
In order to gain further insights into the potential difficulties associated with FPCL application, 
various pilot- and factory scale UHT trials were performed. The samples collected from these 
trials were analyzed to evaluate the extent of FPCL usage on total cholesterol and FFA content 
following thermal processing. For the purpose of this study pilot scale FPCL application trials 
were performed at DuPont® SSA Dairy innovations center Cape Town during the first half of 
2012. The initial results indicated no significant difference between trials with- and without 
FPCL. Similar results were obtained during subsequent trials. The enzyme activity of FPCL was 
consequently determined using an assay based on the formation of free fatty acids following 
incubation with lecithin as substrate. It was found that the FPCL solution used had less than 
25% of the specified activity. When the trials were repeated with fresh FPCL significant 
differences were observed. With the addition of 10 ppm FPCL the ∆T spike observed in control 
trials was eliminated, even after prolonged processing. Operational back pressure buildup was 
also greatly reduced. Visual inspection of the static mixers furthermore revealed less browning 
of the deposits during the enzymated trial. A decreased degree of browning would not only 
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affect the taste of the final product, but will also result in easier cleaning following processing. 
Similar results were obtained during full scale factory application trials. 
Although the initial trials were perceived as failures, the results obtained were invaluable since 
they illustrated a major deficiency in the current marketing model. The recommended dosage for 
FPCL is 10 ppm. Because enzyme activity can be undesirably affected by various factors, 
including improper handling and storage, dosage on a volume per volume basis may result in 
unreliable and erroneous results, such as those observed during the initial pilot scale trials. The 
studies conducted therefore demonstrated the need for an accurate easy to use activity assay 
which could be performed on-site prior to FPCL dosage. The availability of enzyme activity data 
would enable dosage optimization resulting in an increase in product reproducibility. 
Additionally, if enzyme activity is known, this data may be combined with catalytic data of the 
GCAT enzyme to enable dosage adjustment to obtain a product with customer-specified 
characteristics. 
Various authors have described assays whereby the mechanism of GCAT catalysis can be 
investigated, however, complete kinetic characterization of this enzyme has not yet been 
successfully achieved40,48,78,166. This can be ascribed to a combination of difficulties in obtaining 
quality emulsions during the preparation of experimental phospholipid substrates and the wide 
range of possible substrates133. Apart from the problems accompanying the preparation 
substrates for kinetic analysis, neither the substrates nor the products have measurable 
chromatographic characteristics which would allow facile quantification. The assays described 
were therefore performed in end-point style using radio-labeled substrates which could be 
monitored by scintillation counting40,78. End-point style assays allows for general activity 
monitoring. However, such assays have the disadvantage that deviations from the classical 
Michaelis-Menten model of catalysis are not considered.  
In contrast to kinetic analysis using water soluble substrates, lipases, when incubated with 
phospholipases, yield a sigmoidal kinetic profile167. Although the mechanism of GCAT catalysis 
is still not fully understood, it is known that, GCAT, like lipases, catalyze phospholipid hydrolysis 
at lipid-water interfaces. As such the interaction of this enzyme with its substrates is at least a 
two-step reaction82,133. During the first step of this reaction GCAT binds the phospholipid head 
groups in the interface. This is followed by interfacial penetration and formation of the enzyme-
substrate complex82. It is has been proposed that this binding is, at least in part, determined by 
the packaging of the acyl chains82. Although the mechanism of catalysis remains vague, end 
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point assays are not sufficient for kinetic analysis of GCAT catalysis. Availability of kinetic data 
can furthermore be used for the validation of novel activity assays by comparison of the kinetic 
parameters obtained. 
For kinetic analysis of GCAT, accurate methods for the quantification of substrates and/or 
reaction products are needed. Gas chromatography (GC) coupled to flame ionization detection 
(FID) is currently used for the quantification of cholesterol, cholesteryl esters and free fatty acids 
in samples obtained from FPCL application trials. However, sample preparation resulted in the 
destruction of cholesteryl esters. Consistent with this, previous reports by Onorato et al.151, 
indicated that derivatization results in the breakdown of cholesteryl esters. The liberation of 
cholesterol from cholesteryl esters, prior to analysis, will subsequently result in an 
overestimation of the total free cholesterol present in samples containing both cholesterol and 
cholesteryl esters. As a result, this method is not suitable for quality control purposes. 
Alternative methods for the quantification of GCAT reaction products were therefore evaluated.  
The use of high performance liquid chromatography (HPLC) for the quantification of cholesterol 
and cholesteryl esters have been described previously159,168,169. However, although the 
hydrophobic nature of cholesteryl esters result in increased retention on C18 HPLC columns, the 
low maximum UV absorbance of cholesteryl esters results in reduced detection sensitivity. 
Accurate HPLC analysis of mixtures containing both cholesterol and cholesteryl esters are 
therefore limited to samples containing relatively high levels (ppm) of these compounds. Milk 
contains on average 140 ppm cholesterol105. However, while evaluating the existing HPLC 
methods for the quantification of cholesterol and cholesteryl esters, it was shown that these 
methods are not sufficiently sensitive. This is because milk is a complex biological fluid 
containing various compounds which could result in peak overlapping. To compensate for this 
phenomenon, the standards in this study were prepared in fat free skim milk. The method 
described in this study was shown to enable low level detection of cholesterol and cholesteryl 
esters in extracted milk samples. This method requires liquid-liquid sample extraction prior to 
analysis. HPLC analysis of milk samples is therefore time consuming and labour intensive. This 
method is furthermore not sufficiently sensitive for the low levels of detection required for kinetic 
studies. 
Commercially available enzyme based assay kits were subsequently evaluated. It was shown 
that although these methods allows for accurate low level detection of cholesterol, cholesteryl 
esters and FFAs, its use for kinetic studies is limited due to the costs involved. These costs 
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could be reduced by purification of the individual enzymes needed from its bacterial hosts; 
however, this was beyond the scope of the current study. For low level FFA determination in 
milk, the NEFA HR FFA quantification kit (WAKO, Germany) was adapted to a microtiter plate 
assay. The adaptation resulted in a 50% increase in the total number of assays with one kit. The 
cholesterol/cholesteryl ester quantification kit, however, could not be optimized further. Its use 
was therefore limited to quality control in samples obtained from FPCL trials.  
An alternative method involving the use of a stable Lieberman-Burchard (LB) reagent was 
subsequently evaluated for cholesterol quantification during kinetic studies. This method yielded 
the sensitivity needed for kinetic studies; however, solvent extraction was required prior to 
cholesterol determination. Furthermore, with this assay only free cholesterol content can be 
detected. The use of this method is therefore time consuming, labour intensive and requires 
extraction controls for accurate determination of cholesterol in aqueous media. The WAKO 
NEFA HR FFA quantification and Abcam cholesterol/ cholesteryl ester quantification kits were 
therefore used for quantification of GCAT reaction products in milk obtained from application 
trials. For kinetic studies, the NEFA HR FFA proved sufficiently inexpensive and sensitive for 
use in determination of FFAs produced during the study of the hydrolytic activity of GCAT when 
incubated with phospholipids. The transferase activity was monitored with the use of 
radiolabeled tracers since its use enables low level detection of substrates and products and 
eliminates the need for extraction controls. 
While investigating the mechanism of action for GCAT, Buckley78 showed that this enzyme 
could also hydrolyze p-nitrophenyl esters. This author subsequently suggested that p-
nitrophenyl butyrate (pNPB) is hydrolyzed at a rate comparable to phosphatidylcholine 
hydrolysis. The supportive data for this statement was, however, never published. The use of 
pNPB could overcome the difficulties associated with the use of phospholipids as substrates 
since these are non-interfacial monomeric water-soluble substrates170. In this study pNPB was 
used as substrate for the development of a continuous microtiter plate assay for GCAT activity 
monitoring. The benefits of this assay include increased sensitivity, low-cost, ease of use, 
accuracy, reproducibility, versatility and automatability. The assay developed proved sufficiently 
sensitive for activity monitoring in milk samples spiked with 10 ppm FPCL. However, validation 
was required prior to commercial application. 
For validation, the kinetic parameters obtained using the newly developed pNPB assay was 
compared with that obtained using phospholipids as substrates. The assay described by 
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Buckley76 was subsequently adapted to a discontinuous assay in an attempt to determine the 
kinetic parameters, Km and Vmax, of GCAT catalysis. These adaptations included evaluation of 
methods for complete enzyme inactivation following time-point collection and optimized 
monitoring of product formation. Although not optimal, discontinuous assays are suitable for the 
kinetic study of enzyme catalysis. However, complete enzyme inactivation, subsequent to time-
point collection, is essential. Enzyme inactivation using acids have been used successful 
previously. In this study acid treatment resulted in substrate destruction. Enzyme activity was 
subsequently irreversibly inhibited using liquid nitrogen followed by heat treatment at 90°C for 
15 min. The hydrolytic reaction was monitored by FFA formation. During the initial studies 
conducted, using pNPB and de-oiled food grade soy lecithin as substrates, it was found that, in 
contrast to the report by Buckley78, the reaction rates were not similar when it was assumed that 
the definition of a unit of enzyme activity is similar. However, this may be due to the use of 
different substrates during the studies conducted. The definition was subsequently redefined as 
follows: 1 Unit of enzyme activity, when using pNPB as substrate, is the amount of enzyme (in 
mg) which will produce 0.25 µmol p-nitrophenol per minute under the defined assay conditions. 
The results from the described studies indicated that the newly developed assay may be used 
for accurate determination of enzyme activity in FPCL. This assay is furthermore sufficiently 
simplistic for use by moderately skilled personnel and does not require highly specialized 
equipment.  
While attempting to determine the kinetic parameters of GCAT catalysis it was found that the 
reaction velocity of catalysis is significantly affected by the total sonication time during the 
preparation of SUVs. This result suggested that the organizational integrity of SUVs may be 
compromised by extended sonication. In contrast to this, Eklund164 reported that sonication up 
to 60 min does not result in significant phospholipid hydrolysis. In the present study an increase 
in total sonication time resulted in increased levels of FFAs in the SUV suspension. However, 
these conflicting findings may be ascribed to different sonication intensities for the sonicators 
used. Nevertheless, extended sonication resulted in a reduced reaction velocity at substrate 
concentrations in excess of 0.25 mM to yield an inhibitory profile (Figure 5.14). Decreasing the 
total sonication time to 10 min resulted in abolishment of the observed inhibition pattern. 
However, reduction of the sonication time resulted in a reduced overall reaction velocity.  
Since the organizational parameters of the SUVs play a major role during catalysis, these 
results propose that the formation of the enzyme-substrate complex is preceded by binding to 
the head groups of phospholipids in the interface as proposed by Hilton and Buckley82. For this 
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model the phospholipid head groups should be un-obscured and accessible to the GCAT 
enzyme. Phospholipid hydrolysis results in the formation of lysophospholipids. The overall 
characteristics of lysophospholipids differ significantly from that of phospholipids42,171,172. As 
such, the packaging order of lysophospholipids in SUVs would be different from that of 
phospholipids resulting in “kinks” in the walls of the resultant SUV. These abnormalities in the 
vesicular structure would reduce the accessibility of the phospholipid head groups to GCAT. 
Although it remains possible that the observed reduction in enzyme activity may be due to 
inhibition by FFAs, the observation that phospholipid:cholesterol ratios in excess of 2.5:1 results 
in a dramatic decrease in reaction velocity suggest that this is not the case. It has been shown 
that cholesterol is organized alternately with phospholipids in SUV membranes at equimolar 
concentrations136. At phospholipid:cholesterol ratios in excess of 2:1 insertion of cholesterol 
result in disruptions in the organizational structure of SUVs during its preparation. Such 
disruptions would not only affect the vesicular structure but also accessibility to the 
phospholipids by GCAT. These disruptions could subsequently be visualized as the reduction in 
enzyme reaction velocity observed. 
For lipases, interfacial binding is considered to be the rate-limiting step during the reaction with 
lipids. As a result, the kinetic profile for the interaction of lipases with lipids is characterized by a 
lag-phase167. After formation of the enzyme-substrate complex, the catalytic steps take place 
thereby regenerating the enzyme at the interface. As a result, interface binding and penetration 
is not required and lipase catalysis can hereafter be described by Michealis-Menten 
kinetics133,167,173. However, studies by Hilton and Buckley82 reported that GCAT interfacial 
binding is not rate limiting as is the case with lipases. Since no lag phase was observed, these 
results propose that, as suggested by these authors, rapid equilibrium is reached and GCAT 
catalysis can be described by Michaelis-Menten kinetics. 
Although the kinetic studies conducted yielded important information regarding the reaction 
mechanism of GCAT catalysis, we were not able to obtain accurate kinetic data. This is due to 
the complex nature of SUVs as substrates for kinetic studies. As described above, the overall 
reaction velocity varied with sonication time, illustrating the absolute requirement of intact 
interfaces. The apparent kinetic parameters were determined to be as follows (Table 6.1): 
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Table 6.1 Kinetic parameter obtained from kinetic studies conducted in the current study 
Parameter Hydrolytic activity Acyltransferase activity pNPB assay 
Km 0.190 mM 2.83 mM 0.09 mM 
Vmax 15.84 µmol/min/mg protein 102 µmol/min/mg protein 292.4 µmol/min/mg protein 
As described previously, GCAT preferentially catalyzes acyl transfer in the presence of a 
suitable acyl acceptor40,87. Although not accurate, the kinetic results presented suggest that this 
is due to a low affinity for cholesterol. As such, cholesterol is less strongly bound in the active 
site of the protein enabling an increased rate of product release. Since lysophospholipids do not 
partake in subsequent reactions, an increased affinity would result in a lower Vmax. This was 
evident when the apparent Vmax values were compared. 
The difficulties experienced during the studies conducted have also been described during 
biophysical studies of the human lecithin cholesterol acyltransferase170,174. In order to overcome 
these difficulties, the use of catalytically inert ether phosphatidylcholine analogues was 
subsequently suggested.170,174,175. The chemical strength of the ether bond would enable 
prolonged sonication without hydrolysis174. Experimental substrates could subsequently be 
incorporated into previously prepared SUVs without phospholipid hydrolysis. However, it has 
been shown that these substrates may affect catalysis by acting as activators or inhibitors for 
catalysis174. The effect of these catalytically inert substrates should therefore be evaluated prior 
to its use in kinetic studies. This was, however, beyond the scope of this study. 
To ensure successful application, at least 60% of the free cholesterol should be converted 
during incubation without excessive formation of FFAs. With the use of the described methods, 
it was shown that two hours incubation at 4°C was sufficient to convert up to 80% of the free 
cholesterol to cholesteryl ester. Evaluation of the total FFA in milk indicated that dosage with 
FPCL did not result in the overproduction of FFAs. Along with the 50% increase in total 
processing duration, these results indicate that FPCL may be used to reduce the overall cost of 
UHT processing, without a decrease in product quality.  
Since the newly developed activity assay, using pNPB as substrate, was sufficiently sensitive to 
determine enzyme activity in milk samples spiked with FPCL, this assay was used for 
application studies. The Scania processing method is used for the production of 2% milk and 
40% cream in a single process. However, the cream is held at a temperature below the 
inactivation temperature of GCAT for at least 30 min prior to pasteurization165. Since GCAT is 
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active at lipid-water interfaces, it will also be present in the cream. In this study it was shown 
that the cream holding temperatures is not sufficient to destroy GCAT activity. These results 
therefore indicate that FPCL may not be used for processing with the Scania method. To enable 
the use of FPCL in this processing method, a GCAT mutant with increased heat sensitivity may 
be produced by site-directed mutagenesis. However, mutation may also affect the overall 
catalytic activity of the GCAT enzyme. Therefore, currently the use of FPCL is limited to use in 
the production of UHT milk. 
In conclusion, the data presented in this study, as discussed above, clearly demonstrate the 
benefits of FPCL during thermal processing. The studies furthermore revealed the current 
difficulties, and remedies, associated with the application of FPCL in the dairy industry. To the 
best of our knowledge, the current work describes the first partial kinetic characterization of the 
GCAT enzyme. The data obtained from these studies provided evidence for the reaction 
mechanism of GCAT catalysis yielding a better insight into the substrate specificity exhibited by 
this enzyme. Finally, a facile and accurate microtiter plate activity assay was described whereby 
FPCL activity could be validated prior to dosage. 
Taken together the commercial application of the methods described in this study would 
increase FPCL marketability by enabling product tailoring and quality validation. Furthermore, 
the newly developed assay has, upon request from DuPont®, been submitted for validation to 
potentially replace the current global standard operating procedure for activity quantification. 
Although complete kinetic characterization was unsuccessful, this study not only described the 
first kinetic study of GCAT but also provided the first evidence for the proposed mechanism of 
catalysis suggested 23 years ago82. The studies furthermore provided alternative methods 
which could overcome the difficulties experienced. Finally, the current study brings us one step 
closer to a global reduction in the total cost for UHT milk, thereby increasing its availability in 
areas where it is most needed. 
In future studies the use of catalytically inert ether phosphatidylcholine species will be evaluated 
for use as scaffold for full kinetic characterization of GCAT. During these studies, the enzymes 
needed for enzyme-linked quantification of GCAT reaction products could be cloned, expressed 
and purified from experimental hosts, thereby reducing the overall cost per assay. Alternative 
methods for the preparation of SUVs, such as extrusion, will also be investigated in order to 
evaluate the effect on vesicle formation. The degree of substrate degradation will be evaluated 
by microscopy and FFA liberation. Alternative assay methods, such as interfacial tensiometry, 
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will also be attempted since this method would allow continuous activity monitoring using the 
natural substrates, lecithin and cholesterol. Finally, in order to enable in-factory activity 
verification, the plausibility dip-strip type activity assays will be investigated. These assays will 
rely on the use of either natural or synthetic substrates immobilized on a suitable surface. 
Enzyme activity could subsequently be estimated by comparison to a colored activity standard 
sheet similar to the modern-day pH strip method. 
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